Protein Sequencing Market Updated Business Strategies, Growth and Opportunities|Agilent Technologies – PharmiWeb.com

Pune, Maharashtra, India, July 31 2020 (Wiredrelease) MarketResearch.Biz : The recent report posted via MarketResearch.Biz on Protein Sequencing market offers critical market insights in conjunction with targeted segmentation evaluation. The report examines key using elements which might be anticipated to drive the increase of the market.

Global Protein Sequencing Market Research Report offers crucial data on numerous market situations, for example, ability improvement elements, elements controlling the advancement, market possibilities, and risks to the global market. Also, the report widely facilities round competitive evaluation of Protein Sequencing Market. The competitive evaluation section includes key producers, recent players, providers, market strategies, ability chances, operation panorama, and evaluation of the traits of the Protein Sequencing market. The market consequences are targeted by round the present market scenario. To gauge and expect the competitive scenario on this market. This report will likewise assist all of the producers and speculators to have an advanced comprehension of the investments to recognize wherein the market is heading.

For Better Understanding, Request A Free Pdf Sample Copy Of Protein Sequencing Market Here@ https://marketresearch.biz/report/protein-sequencing-market/request-sample

(***Our FREE SAMPLE COPY of the report offers a quick advent to the studies report outlook, TOC, a listing of tables and figures, an outlook to key players of the market, and comprising key regions.)

Leading players of Protein Sequencing including:

Agilent Technologies Inc, Bioinformatics Solutions Inc, Charles River Laboratories Inc, Proteome Factory AG, Rapid Novor Inc, Selvita SA, SGS SA, Shimadzu Corporation, Thermo Fisher Scientific Inc, Waters Corporation

Segmentation on the Basis of Component: Sample Preparation Products & Services, Protein Sequencing Products, Protein Sequencing Services. Segmentation on the Basis of Technology: Edman Degradation, Mass Spectrometry. Segmentation on the Basis of Application: Biotherapeutics, Genetic Engineering. Segmentation on the Basis of End User: Academic Institutes & Research Centers, Pharmaceutical & Biotechnology Companies

Download Now And Browse Complete Information On The COVID 19 Impact Analysis On Protein Sequencing Market:https://marketresearch.biz/report/protein-sequencing-market/covid-19-impact

Protein Sequencing Report Covers Following Questions:

1. What will the market increase rate, increase momentum of Protein Sequencing market

2. What is the envisioned size of the rising Protein Sequencing market in 2029?

3. Which section is anticipated to account for the most important Protein Sequencing market percentage by 2029?

4. What are sales, revenue, and value evaluation by areas of Protein Sequencing market?

5. What are the market risk, market possibility and market review of the Protein Sequencing market?

6. Who are the distributors, dealers, and buyers of Protein Sequencing market?

Moreover, the report in brief research the overall performance of each historic statistics in conjunction with the current traits. It consists of an entire evaluation of various attributes inclusive of production base, type, and size. This report evaluates the market segmentation in conjunction with the competitive panorama worldwide in addition to the local level. The report additionally discusses approximately the growing want for Protein Sequencing market.

Reasons for Buying this Report

The worldwide Protein Sequencing market report offers a forward-searching attitude on Driving and restraining elements of the market increase.

Ten-year forecast assessed on the premise of how the market is expected to grow

Future evaluation is moreover supplied on how the market is predicted to grow

Past market dynamics of the past years

Helps in know-how the important thing product segments and their future estimations

Focused evaluation of converting competitive dynamics to recognize the procedures utilized by the numerous key players withinside the market

Any Query? Feel Free To Enquire Here: https://marketresearch.biz/report/protein-sequencing-market/#inquiry

Report on Global Protein Sequencing Market 2020 contains of 10 Sections in Table as follows:

Industry Overview of Protein Sequencing: Includes numerous definitions, specs in conjunction with its features, and applicability.

Protein Sequencing Manufacturing Cost & Price Structure Analysis: Raw Material required and their suppliers, price shape evaluation on the subject of production, structural evaluation of promoting price, break-even factor evaluation, and procedure evaluation.

Production Description: Capacity and Commercial Production Date of Protein Sequencing Major Manufacturers in 2020, Manufacturing Plants Distribution, R&D Status, and Technology Source and Raw Materials Sources Analysis.

Global Protein Sequencing Overall Market Overview: Overall Market Analysis starting from Production to Revenue

Global Protein Sequencing segmentation:

By Type: Sales and Factors impacting the increase in sales.

By Application: Consumer evaluation in conjunction with the end-user evaluation.

Analysis of Major Manufacturers of Protein Sequencing across the world: Examination of every Company profiles, picture of the object and details, sales, preceding costs, income, Gross Margin Analysis, Business Region Distribution Analysis

The trend of Protein Sequencing Market: Protein Sequencing Market Trend Analysis, Market Size (Volume and Value) Forecast, Regional Market Trend, Market Trend via way of means of Product Type and Applications.

Browse The Complete TOC of the Report: https://marketresearch.biz/report/protein-sequencing-market/#toc

The Protein Sequencing market report reads pin-direct evaluation for converting extreme dynamics in regards to converting factors that drive or limits market improvement. The report is comprehensively visualized to forecast the market factor of view and possibilities wherein it has an extension to expand in the future. Basically, the report segregates the potential of the market withinside the current and the upcoming opportunities from numerous edges in detail.

About Us:

MarketResearch.Biz is a specialized market research, analytics, and solutions company, offering strategic and tactical support to clients for making well-informed business decisions. We are a team of dedicated and impassioned individuals, who believe strongly in giving our very best to what we do and we never back down from any challenge. The company offers services such as data mining, information management, and revenue enhancement solutions and suggestions. We cater to industries, individuals, and organizations across the globe, and deliver our offerings in the shortest possible turnaround time.

Contact Us:

Mr. Benni Johnson

Prudour Pvt. Ltd.

420 Lexington Avenue,

Suite 300 New York City, NY 10170,

United States

Tel: + 1-347-826-1876

Website: https://marketresearch.biz/

This content has been published by MarketResearch.Biz company. The WiredRelease News Department was not involved in the creation of this content. For press release service enquiry, please reach us at contact@wiredrelease.com.

Go here to read the rest:

Protein Sequencing Market Updated Business Strategies, Growth and Opportunities|Agilent Technologies - PharmiWeb.com

The Tyranny of Merit: what’s become of the common good? – The London School of Economics and Political Science

Join us for this online public event with Michael Sandel who will be discussing his latest book,The Tyranny of Merit: What's Become of the Common Good?

In this new bookSandel argues that to overcome the polarised politics of our time, we must rethink the attitudes toward success and failure that have accompanied globalisation and rising inequality. Sandel highlights the hubris a meritocracy generates among the winners and the harsh judgement it imposes on those left behind. He offers an alternative way of thinking about success - more attentive to the role of luck in human affairs, more conducive to an ethic of humility, and more hospitable to a politics of the common good.

Michael Sandelteaches political philosophy at Harvard University. His writingson justice, ethics, democracy, and markets--have been translated into 27 languages. His course Justice is the first Harvard course to be made freely available online and on television. It has been viewed by tens of millions of people around the world, including in China, where Sandel was named the most influential foreign figure of the year. (China Newsweek)

Sandels books relate enduring themes of political philosophy to the most vexing moral and civic questions of our time. They includeWhat Money Cant Buy: The Moral Limits of Markets;Justice: Whats the Right Thing to Do?; The Case against Perfection: Ethics in the Age of Genetic Engineering; Public Philosophy: Essays on Morality in Politics; Democracys Discontent: America in Search of a Public Philosophy; andLiberalism and the Limits of Justice.

You can order the book,The Tyranny of Merit: What's Become of the Common Good?, (UK delivery only) from our official LSE Events independent book shop,Pages of Hackney.

Andrs Velasco (@AndresVelasco) is Professor of Public Policy and Dean of the School of Public Policy at the London School of Economics and Political Science.

TheSchool of Public Policy(@LSEPublicPolicy) is an international community where ideas and practice meet. Our approach creates professionals with the ability to analyse, understand and resolve the challenges of contemporary governance.

Twitter Hashtag for this event:#LSESandel

View post:

The Tyranny of Merit: what's become of the common good? - The London School of Economics and Political Science

Draper to Build on its Biosecurity Tool Development for IARPA – Yahoo Finance

The Office of the Director of National Intelligence has contracted with Draper to develop new kinds of detection systems that can identify whether engineered organisms have been created from natural organisms.

CAMBRIDGE, Mass., July 28, 2020 /PRNewswire-PRWeb/ --Advances in gene editing technology and improved access via the web have substantially increased the prevalence of engineered organisms in our world. Benefits range from pest-free crops to reduction in the spread of infectious diseases, but along with these advantages comes a need to identify good bioengineering from the kind that might pose a threat.

To address this challenge, the Office of the Director of National Intelligence (ODNI) has contracted with Draper to develop new kinds of detection systems that can identify whether engineered organisms have been created from natural organisms. Officials at ODNI's Intelligence Advanced Research Projects Activity (IARPA) have awarded Draper a two-year Phase 2 contract under its Finding Engineering-Linked Indicators (FELIX) program, for a total contract value worth $7.8 million.

The award calls for Draper to continue development of two distinct lab-based genetic tests, custom bioinformatics pipelines that contextualize DNA sequencing data, and miniaturized microarray hardware with a specialized design. The devicesmaller than a postage stampallows multiple rounds of genetic tests on any organism, from a broad variety of sources including soil and water. Potential applications include biothreat detection, environmental monitoring and food inspection.

The microarray can be equipped with up to 10,000 surface probes to help identify genetic engineering. The device and associated lab methods combined are sensitive enough to pick out a ratio of a single engineered organism against a complex environmental background containing millions of natural organismsa signal-to-noise ratio that is a significant improvement over current methods.

Kirsty McFarland, molecular microbiologist and Principal Investigator on Draper's FELIX program, says the technologies under development will be able to detect genetic signatures that are not accessible with current technologies. "Current methods for detecting engineered organisms, in soil for example, read only a subset of all the genetic material that's present in the sample, typically through next-generation sequencing. That process inherently misses information and does not reveal important genetic context," she said. She noted that one gram of soil may contain up to one billion microbial genomes.

To accompany each genetic identification system, Draper also developed two custom bioinformatics tools, which include a computational pipeline and visual dashboard that convert lab data into actionable intelligence that users can see on a computer screen.

Draper's FELIX contract is the result of close collaboration between the Synthetic Biology group and Draper's Special Programs Office.

Draper At Draper, we believe exciting things happen when new capabilities are imagined and created. Whether formulating a concept and developing each component to achieve a field-ready prototype or combining existing technologies in new ways, Draper engineers apply multidisciplinary approaches that deliver new capabilities to customers. As a not-for-profit engineering innovation company, Draper focuses on the design, development and deployment of advanced technological solutions for the world's most challenging and important problems. We provide engineering solutions directly to government, industry and academia; work on teams as prime contractor or subcontractor; and participate as a collaborator in consortia. We provide unbiased assessments of technology or systems designed or recommended by other organizationscustom designed, as well as commercial-off-the-shelf. http://www.draper.com

SOURCE Draper

Read the original:

Draper to Build on its Biosecurity Tool Development for IARPA - Yahoo Finance

Halo Infinite should close the ring that is Master Chief and Cortana’s saga – GamesRadar+

Halo Infinite is coming and with it should be the end of Master Chief's 20-year story.

It certainly seems like 343 Industries is teeing Halo Infinite up to be the final chapter in the epic saga that is John-117. The trailer that debuted at the Xbox Games Showcase ends with Chief coming face-to-face with a Banished leader whose monologue implies the Chief's demise: "But here you now stand. This is my last fight. A true test of legends, our story will outlive us both. Set a fire in your heart, Spartan. Bare your fangs, fight hard, die well."

With the news that Halo Infinite is meant to be the last standalone Halo title for a decade, there's nothing left for 343 to do except to kill their darling or in this case, their Master. The blatant throwback to Halo: Combat Evolved in the Halo Infinite box art and the game's nostalgic, sunny graphics hammers home the idea that Halo Infinite will close the loop that is the Halo saga. It's a narrative Halo ring, and this is the final piece.

Here's how all roads point to Halo Infinite closing the door forever on Master Chief, Cortana, and the Halo universe as we know it, and why that's a good thing.

While Halo lore is far more complicated than the gameplay would have you think, it's clear that the epic story has been funnelling us towards a logical conclusion. Let's recap, as it can get a bit convoluted.

Long before the events of Halo: Reach, humans were an advanced, spacefaring species in the running to obtain the Mantle of Responsibility. The Mantle is an ideology before it is an object, the creation of the Precursors (an ancient species responsible for genetically engineering many of the races in the galaxy). It represents the obligation of the most advanced race to protect lesser life forms in the galaxy but the Forerunners, another alien race, believed they were the rightful inheritors of the Mantle, and began a long war that led to them forcing humans to live in a pre-technological state on a planet known as Earth.

The term "Reclaimer" is important here it's used to refer to the species chosen to inherit the Mantle in particular, it refers to humans who carry a special genetic code written in by a Forerunner known as the Librarian. Reclaimers can activate Forerunner technology it's why Master Chief comes damn near close to activating the ring in Halo: Combat Evolved, and why he seems to know his way around the tech despite never having encountered it before. It's also why the Covenant have to kidnap humans to activate Forerunner tech despite believing they deserve the mantle, none of the Covenant races are Reclaimers. Sucks to suck.

The genetic code that Chief contains is also responsible for the creation of other SPARTANs and Cortana's creation - the Librarian planted seeds that led to technological advances like the SPARTAN program and Smart AI. This speaks to the larger picture of the ties that bind Chief and Cortana.

Sacrifice is a common theme in the Halo franchise, though the ultimate sacrifice (giving one's life) has thus far been reserved for characters who aren't Master Chief and Cortana though not for their lack of trying.

In Halo: Reach, every member of Noble Team (save one) sacrifices themselves to ensure humanity can stand against the Covenant. At the end of Halo 3, it appears Chief has sacrificed himself to save humanity, although he obviously ends up surviving. At the end of Halo 4, you control Chief as he desperately claws his way to a nuclear warhead that he detonates with his hands to save humanity. Again, Chief doesn't die, despite being centimeters away from a nuclear explosion - because Cortana sacrifices herself to save him.

By Halo 5, it's clear that Cortana is still alive, though driven to madness by rampancy (a sort of deterioration that advanced AI suffer after being online for more than seven years"), and determined to get her hands on the Mantle of Responsibility, which she claims belongs to AI.

For Halo: Infinite to narratively and thematically close the Halo loop, Chief should sacrifice himself to stop the Banished (and likely Cortana and the Created, a faction of rogue artificial intelligence she founded). But there's arguably an even bigger sacrifice, in John's future Cortana herself, the closest thing this tragic figure has had to a loved one since his brief childhood.

And that may very well be the core of this Halo epic. Master Chief and Cortana's relationship, brought together by destiny, by the genetic gifts bestowed upon humanity by the Precursors.

"We go together," Chief tells Cortana at the end of Halo 4. It's a simple statement that profoundly states his feelings for her. After she sacrifices herself for Chief, a montage plays of their interactions across the series, hammering home the notion that this bond goes beyond a soldier tasked with protecting an AI. She is, after all, the only real thing that gives Chief pathos in the entire series, and that's thanks to 343 deciding to lean into that relationship when they took the Halo helm.

Before that, Chief is merely a faceless super soldier with a pretty solid moral compass, one-lining his way through a franchise in order to save the world and his snarky computer lady. Cortana and Chief are the beating heart of the Halo franchise but I think it's time for that heart to stop.

With the back-to-back fake-outs of Halo 3 and Halo 4, the stage is set for Chief to make the ultimate sacrifice. Cortana is still alive at the end of Halo 5, after having brutally betrayed him in order to continue on her rampage to get her hands on the Mantle. As the Banished leader said in the Halo Infinite trailer, it is indeed time for John-117 to "set a fire" in his heart in order to "die well." But not before he takes Cortana with him.

See the rest here:

Halo Infinite should close the ring that is Master Chief and Cortana's saga - GamesRadar+

Where Did COVID-19 Really Come From? – besacenter.org

Wuhan Institute of Virology main entrance, Wuhan City, Hubei province, China, image via Wikimedia Commons

BESA Center Perspectives Paper No. 1,664, July 28, 2020

EXECUTIVE SUMMARY: The questions of the true genomic origin as well as the direct source of the initial SARS-CoV-2 strain that infected Patient Zero in China, an event that ultimately unleashed COVID-19 on the world to devastating effect, are hotly debated and highly consequential. Both science and intelligence will contribute to uncovering the evidence needed to answer these questions conclusively.

Behind the great challenge of how to deal with the global COVID-19 pandemic are the questions of the viruss true genomic origin and direct source. These questions will likely be answered through synergies between science and intelligence, the combined findings of which will ultimately converge into a critical mass of evidence.

SARS-CoV-2 is the strain of coronavirus that causes COVID-19. According to unofficial reports and taking into account the viruss incubation period, Patient Zero was apparently infected in Wuhan, China in October or November of 2019. However, it was not until December 31, 2019 that the Wuhan Municipal Health Commission issued an alert that there was a cluster of cases of viral pneumonia in Wuhan. At the time, the initial source of the virus was said to have been an unidentified infected animal from the Wuhan wet market. This claim was later abandoned by China.

An alternative possibility is that the viruswhether natural, man-made, or otherwise modifiedleaked from a lab at the Wuhan Institute of Virology (WIV) or another Wuhan-based facility.

In 2015, an article in Journal of Defence Studies profiled the Chinese biological warfare program and noted that the WIV, basically a civilian facility, dealt with certain pathogens, including the SARS virus.In 2019, the WIV was involved in the improper dispatch of highly virulent viruses (not coronaviruses) from Canada to China, which bolstered that case. In January 2020, the WIV was identified as a facility from which SARS-CoV-2 had possibly leaked.

Whether or not the WIVs labs, civilian or otherwise, were holding the COVID-19 virus, it could be an intact natural virus strain. A lab leak might have occurred via an accidentally infected worker, an infected lab animal, or a technical failure.

In February 2020, Maj. Gen. Prof. Wei Chen, a prominent Chinese biological warfare expert affiliated with the militarys Beijing Institute of Biotechnology, was appointed head of the WIV wing, which is at biosafety level 4 (the highest level). In Wuhan, she collaborated with the Wuhan Institute of Biological Products and Wuhan-based academic institutions. Her object was to develop vaccines, anti-sera, and other countermeasures to guard against the spreading COVID-19 virus.

In the US, Prof. Francis Boyle claimed on February 2 that the virus had been held at the WIV as a bioweapon and leaked from its lab. Sen. Tom Cotton amplified the lab virus theory on February 17, when he said the virus might have leaked from the WIV. Concrete evidence beyond the circumstantial was not offered, which discredited the theory.

On the intelligence level, however, evidence was being accumulated that gave credence to the possibility of a Chinese lab leak. On April 5, British intelligence indicated that the features of SARS-CoV-2, as well as the extensive studies conducted in Wuhan on similar coronaviruses, rendered the lab script a credible alternative view. US intelligence officials said there is no evidence the pandemic coronavirus was created in a laboratory as a potential bio-weapon or engineered, but those words do not negate the possibility of a lab leak.

A few days after that statement, nine officials from the current and former US intelligence and national security services who are familiar with the investigations in progress said the possibility that the pandemic was triggered by an accident at a research facility in Wuhan was certainly real and was absolutely under scrutiny at the highest level. Several weeks later, President Trump noted with a high degree of confidence that the outbreak emanated from the WIV, though he added that he could not reveal details.

US Secretary of State Mike Pompeo (who was head of the CIA until April 2018) said that in addition to the WIV, There are multiple labs where the Chinese Communist Party is working on various levels of pathogens. He has also made these statements:

He has also said, however, that The intelligence community is still figuring out precisely where this virus began. We are all trying to figure out the right answer and There are different levels of certainty expressed at different sources of information. Pompeo added that he has no reason to doubt the US intelligence communitys consensus that the virus was not man-made or genetically modified.

A contemporaneous statement from the office of the acting Director of National Intelligence confirmed this, saying the US intelligence community

concurs with the wide scientific consensus that the COVID-19 virus was not a man-made or genetically modified virus. The Community will continue to rigorously examine emerging information and intelligence to determine whether the outbreak began through contact with infected animals (a natural contagion) or if it was the result of an accident at a laboratory in Wuhan.

At about the same time, a preliminary US government analysis compiled from open information said there is no smoking gun to blame the virus on either the Wuhan Institute of Virology or the Wuhan CDC branch, but there is circumstantial evidence to suggest such may be the case while all other possible places have been proven to be highly unlikely.

One US intelligence viewpoint is that there is growing evidence that the virus likely came into being in a Wuhan laboratory, not as a bioweapon but as part of Chinas effort to demonstrate that its ability to identify and combat viruses is equal to or greater than that of the US. Further, a majority of the 17 agencies that provide and analyze intelligence for the US government concurred in May that they believe the pandemic started after the virus leaked from a Wuhan lab, a claim based mostly on circumstantial evidence.

Sen. Tom Cotton, meanwhile, who is a member of the US Senate Select Committee on Intelligence, bolstered his lab leak argument with details based on unclassified general information:

All the evidence at this point points to two labs in Wuhan, while no evidence at all points to the wet market in Wuhan. The fact that they research coronaviruses, that they used bats, that they have a history of bad safety practices, that Patient Zero had no contact with the wet market, all of that is circumstantial evidence to be sure. But in intelligence questions, we rarely get direct or conclusive evidence. So I agree that all of the evidence, albeit circumstantial, points directly at those labs. And if the Chinese Communist Party has evidence to the contrary, they need to bring it forward to the world.

Cotton added, Whether the virus was genetically modified or engineered is a highly technical, scientific question. And the weight of scientific opinion right now [May 5, 2020] says that, no, this was a naturally occurring virus. But a naturally occurring virus can, of course, be present in a laboratory where its being studied.

Statements made afterward by US Assistant to the President Peter Navarro were sharper:

I think personally the virus was spawned in a P4 weapons lab (WIV) The Ground Zero patient in Wuhan was within yards of that P4 lab I think its incumbent on China to prove that it wasnt that lab The Chinese spawned the virus, not created it. That virus was a product of the Chinese Communist Party, and until we get some information about what happened in those labs or what happened in that wet market, we know that the virus was spawned in China. Whether it was purposefully spawned in the Chinese lab is still an open question.

Navarro apparently meant that in a classified military lab of WIV (nominally, and largely in reality, an institute affiliated with the Chinese Academy of Sciences), the Chinese enabled the virus to emerge, whether or not they intended to give rise to the virus that actually came into being. The roles of that lab and the wet market in propelling the initial outbreak remain to be explained. One possibility is that infected animals from the lab were illegally sold in the market. This would fit Navarros description of Patient Zero, who came down with the virus before the market became associated with the contagion.

At any rate, Navarrolike Cottonsaid it is Chinas responsibility to provide evidence of a natural contagion of SARS-CoV-2. As long as China fails to do this, the contagion is to be regarded as unnatural.

In late June, an unclassified report by the US State Department referred to Chinas biological warfare program at large, stating:

The United States does not have sufficient information to determine whether China eliminated its assessed biological warfare program, as required under Article II of the Convention [Chinassubmissions to the convention] have neither documented that offensive program, nor documented that Chinahas eliminated the program or any remaining biological weapons [as required under the accord].

British military and intelligence expert Col. (ret.) Richard Kemp said he had been told by an unnamed insider that there was a very high probability that SARS-CoV-2 was released unintentionally from a Wuhan lab and was a man-made variation. He said he was tipped off about a warfare facility near Wuhan by a senior foreign intelligence source who said analysts strongly suspected Chinas WIV.

Kemp added,

It is very likely to be the case. I was also led to believe governments were very unlikely to come out and say it outright, but that China had been made aware that intelligence agencies had significant evidence. The virus came from an animal that had been involved in testing in the WIV, and had ended up in the wet market. It was believed then and now that an unscrupulous member of staff sold it for personal profit without considering it may be infected. That is how it got out a postulation known to be true but [that] cannot be backed up by absolute evidence.

While this report was highly informative, it has not been verified or refuted.

Australian PM Scott Morrison declined on April 30 to buy into the lab theory, stating that he had not seen anything that suggests that conclusively, while virus emergence from [the] Wuhan wet market appears more likely. Other voices in the Australian government held that it would be unwise to rule out the possibility of the lab scenario. Australian Chair of the Parliamentary Joint Committee on Intelligence and Security Andrew Hastie was diplomatic on the question: I think there are a lot of contentions, and all of them deserve to have a serious consideration. We have to be open-minded about all possibilities.

The specific evidence obtained by the US intelligence community has not been revealed in detail. More concrete intelligence information is generally given a higher classification as it is inadvisable to disclose classified intelligence that could give the opponent room for maneuver. This means there is a sort of Catch-22 between the persuasiveness of evidence and the intelligence communitys freedom to publicize it. This would certainly apply to evidence proving the unnatural origin and source of COVID-19. In any event, it is hoped that a critical mass of convincing information will soon be reached and brought out in detail.

Possible intelligence footholds could ultimately prove to be a key to answering the big questions. A variety of firms and scientific institutions, mainly in the US, Canada, France, Australia, and Singapore, have been collaborating with the WIV (as well as other bio-labs engaged with coronaviruses in Wuhan). The British intelligence community also likely still maintains significant ties in Hong Kong. With that said, it is by no means assured that all those potential intelligence footholds are willing to fully cooperate with intelligence collectors and forward information, either documented or undocumented.

There is a similar challenge regarding the full sharing of intelligence within NATOs Joint Intelligence, Surveillance and Reconnaissance system, as well as within the Five Eyes intelligence community (the US, Britain, Canada, Australia, and New Zealand). Taiwan, India, South Korea, and Japan might also collect valuable information due to their proximity to and interfaces with China.

Former US presidential adviser Steve Bannon revealed on July 13 that They dont speak with the press yet, but there are people from Wuhans laboratory and from other laboratories who have come to the West and are wrapping up evidence in favor of the Chinese Communist Party. I think people will be shocked. According to him, lab staff have been leaving China and Hong Kong since mid-February and certain defectors are working with the FBI to figure out what happened at Wuhans laboratory. US intelligence, in conjunction with British counterintelligence, is preparing a lawsuit.

If this broad international intelligence process takes shape optimally, an informational critical mass will likely be reached eventually that either clears or identifies the WIV (or a similar lab) as the origin and source of the pandemic. How much of that information will be made public is another issue, considering both its classification and sensitivity and Chinas immense global geostrategic position.

Intelligence is generally proof-free, in scientific and/or juridical terms. Proofs obtained by intelligence systems are certainly desirable and do occur, but substantively, intelligence analysis relies on the tracing and deductive recognition of pertinent evidence, even if circumstantial. At times, this essential characteristic of intelligence analysis can be a great disadvantage, but it is rarely insurmountable.

A proper intelligence estimate will always say There are indicative or indirect data pointing to X rather than There is no proof or hard evidence of X. Broadly speaking, any analytical context that is not merely technical but relies on deduction might ultimately reach the point that evidence, even if circumstantial, allows a solid pragmatic conclusion to be drawn. These assessments are considered valid due to their plausibility, even those that are inferential.

In the case of the origin of the COVID-19 pandemic, because of geopolitical considerations and constraints, this approach will probably not suffice to reach a clear-cut conclusion one way or the other.

Intelligence communities can produce (if not autonomously) scientific judgments as well. The scientific dimension related to SARS-CoV-2 is no less complex, in its way, than the intelligence one. Within the scientific dimension polarity prevails, at least for now.

On one side is the concept that both the origin and the source of SARS-CoV-2 are completely natural, and on the other is the idea that its origin was an engineered virus (whether designed as a bioweapon or for other purposes). Between those two polar concepts lies a wide range of variations and combinations, since viral affinities toward humans (which are exceptional in the case of SARS-CoV-2) can be attained or enhanced in different ways. One hypothesis is that the origin of COVID-19 was a manipulated virus, which, if true, is probably technically unprovable.

Be that as it may, synthetic virology and genetic engineering are not the only ways humans can manipulate the evolutionary course of viruses. It could be that a wild-type virus underwent a spontaneous genetic drift after being administered to or seeded in experimental animals or tissue cultures. This would constitute human intervention or manipulation even though it is neither synthesis nor engineering.

A man-made virus literally means it is wholly synthetic, but there are variations on the term man-made like partly synthesized, hybrid, recombinant, mutant, and so on, all of which are artificial and preplanned. Often, too, evolutionary processes leading to similar viruses take place spontaneously in viruses due to man-induced courses in a lab. Chinese biotechnology has mastered both modes of virus handling.

Two recent scientific observations might be highly significant. One is that humans are not yet clever enough to create a virus as sophisticated as SARS-CoV-2, which means it evolved endogenously within an animal or a tissue culture. The other is that certain components of the virus suggest an interaction with a host immune system, which means it could not have formed solely within a tissue culture. If this is true, the implication is that the virus came into being in an animal, either in nature or in a lab.

One possibility, then, is that a wild-type virus was first propagated repeatedly in human tissue cultures, and the resulting spontaneously upgraded virus was subsequently used to experimentally infect monkeys or ferretsone of which then accidentally infected a person in the lab. (The WIV has long been routinely supplied with rhesus monkeys from the Macaque Breeding Base in Suizhou City.)

It is also possible that a wild-type virus became highly human-adapted through a fully natural genetic process that has not yet been pinpointed, and that it infected a person (either through natural contagion or in a lab where it was held). The probability of such a specific adaptational genetic shift taking place completely in nature has been questioned, though various scientific analyses do rely on it.

There is also always the chance that a wild-type strain that would unequivocally demonstrate natural evolution has not yet been isolated from an animal, or has been isolated but not yet sequenced, or has been sequenced but not published. The point is whether or not the existing genomic data relating to coronaviruses at large are sufficiently representative to be relied on for comparative phylogenetic analyses of the pandemic virus in order to determine whether the genomic difference between the pandemic virus and other coronaviruses is an outcome of a natural evolutionary process or of a non-natural, human-induced technical process.

There have also been observations that the extent (rather than the content) of the genetic shift undergone by the pandemic virus prior to its emergence is discordant with the regular spontaneous course of the natural evolutionary clock.

The timing of Patient Zeros infection and subsequent presentation with the disease is a medical matter, but intelligence can play a role here. For example, information could emerge that verifies that on a certain date a technical mishap occurred in a lab while scientists or technicians were handling monkeys that were infected by a virulent, SARS-like coronavirus. Information could also be gathered that on a certain date a lab technician got ill and was later diagnosed as Patient Zero. Such information may, indeed, have already been obtained and corroborated.

Alternatively, it is conceivable that Patient Zero contracted the virus (or a closely related precursor virus) in a bat cave in Yunnan province and then returned, asymptomatic, to Wuhan. If that is the case, an intermediate animal host species between bat and man is not evolutionarily essential. Still, the fact that nothing of the kind has been reported by China appears to imply that it did not take place.

One hypothesis that might be significant is that the progenitor strain of SARS-CoV-2 was a virus that infected six miners in Mojiang, Yunnan Province in 2012. The mine in which they contracted their illness is known to be a breeding ground of bats infected abundantly with assorted coronaviruses. The virus killed three of the six infected miners.

The virus was isolated at the WIV from specimens taken from the infected miners, as discovered recently by Dr.Jonathan Latham and Dr. Allison Wilson. The details are contained in an unremarkable Chinese masters thesis called Analysis of Six Patients with Severe Pneumonia Caused by Unknown Viruses from Kunming Medical University.

According to the hypothesis of Latham and Wilson, the crucial genetic human-adapted shift the virus underwent (or a major part of it) took place during the infection of one or more of the miners. This shift could have continued while the isolated virus was being investigated at the WIV, prior to the initial COVID-19 outbreak and/or during the infection of Patient Zero in Wuhan. This scenario is consistent with the lab leak theory, whether the virus partially evolved in the WIV or not.

The origin and source of the SARS-CoV-2 virus are still a puzzle, and they need to be explained. The World Health Organization said on July 7:

WHO experts will travel to China to work together with their Chinese counterparts to prepare scientific plans for identifying the zoonotic source of the SARS-CoV-2 virus. The experts will develop the scope and TOR for a WHO-led international mission. Identifying the origin of emerging viral disease has proven complex in past epidemics in different countries. A well planned series of scientific researches will advance the understanding of animal reservoirs and the route of transmission to humans. The process is an evolving endeavor which may lead to further international scientific research and collaboration globally.

Zoonotic refers to an infected animal source, including lab animals.

The WHO system responsible for gathering information about emerging and spreading pathogens worldwide is called Epidemic Intelligence from Open Sources. It remains to be seen how far the WHO investigative mission to China will go (if at all) beyond obtaining open information. It is to be hoped that the mission will conduct a comprehensive, vigorous, and objective investigation and will ignore whatever pressures it might face.

Two WHO experts have gone to China as a first step. Executive director of the WHO Health Emergencies Program Mike Ryan underlined that figuring out the true source of the virus requires detective work that will entail an integrated approach and a lot of hard work.

There are important common denominators between intelligence and science, two paramount spheres that are fundamentally different in both essence and substance. A merging of these spheres would be immensely complicated. They are better used to complement one another. The lines between them are often subtle, with a degree of overlap. It is very much to be hoped that they will be able to work together constructively to reach a critical mass of information on the origin and source of COVID-19.

View PDF

Lt. Col. (res.) Dr. Dany Shoham, a microbiologist and an expert on chemical and biological warfare in the Middle East, is a senior research associate at the Begin-Sadat Center for Strategic Studies. He is a former senior intelligence analyst in the IDF and the Israeli Defense Ministry.

Go here to see the original:

Where Did COVID-19 Really Come From? - besacenter.org

Trending Now: Molecular Scissors Technology Market Detailed Analysis of Current Industry Figures With Forecasts Growth by 2026| Cibus, Thermo Fisher…

LOS ANGELES, United States: QY Research has recently published a report, titled Global Molecular Scissors Technology Market Report, History and Forecast 2015-2026, Breakdown Data by Companies, Key Regions, Types and Application. The research report gives the potential headway openings that prevails in the global market. The report is amalgamated depending on research procured from primary and secondary information. The global Molecular Scissors Technology market is relied upon to develop generously and succeed in volume and value during the predicted time period. Moreover, the report gives nitty gritty data on different manufacturers, region, and products which are important to totally understanding the market.

Key Companies/Manufacturers operating in the global Molecular Scissors Technology market include: Cibus, Thermo Fisher Scientific, Inc., Merck, Recombinetics, Sangamo Therapeutics, Editas Medicine, Precision BioSciences, Intellia Therapeutics, Inc., Caribou Biosciences, Inc, Cellectis

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1674037/global-molecular-scissors-technology-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Molecular Scissors Technology market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Molecular Scissors Technology Market Segment By Type:

Cas9TALENs and MegaTALsZFNOthers

Global Molecular Scissors Technology Market Segment By Application:

Cell Line EngineeringAnimal Genetic EngineeringPlant Genetic EngineeringOthers

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Molecular Scissors Technology market.

Key companies operating in the global Molecular Scissors Technology market include Cibus, Thermo Fisher Scientific, Inc., Merck, Recombinetics, Sangamo Therapeutics, Editas Medicine, Precision BioSciences, Intellia Therapeutics, Inc., Caribou Biosciences, Inc, Cellectis

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1674037/global-molecular-scissors-technology-market

TOC

1 Market Overview of Molecular Scissors Technology1.1 Molecular Scissors Technology Market Overview1.1.1 Molecular Scissors Technology Product Scope1.1.2 Market Status and Outlook1.2 Global Molecular Scissors Technology Market Size Overview by Region 2015 VS 2020 VS 20261.3 Global Molecular Scissors Technology Market Size by Region (2015-2026)1.4 Global Molecular Scissors Technology Historic Market Size by Region (2015-2020)1.5 Global Molecular Scissors Technology Market Size Forecast by Region (2021-2026)1.6 Key Regions Molecular Scissors Technology Market Size YoY Growth (2015-2026)1.6.1 North America Molecular Scissors Technology Market Size YoY Growth (2015-2026)1.6.2 Europe Molecular Scissors Technology Market Size YoY Growth (2015-2026)1.6.3 China Molecular Scissors Technology Market Size YoY Growth (2015-2026)1.6.4 Rest of Asia Pacific Molecular Scissors Technology Market Size YoY Growth (2015-2026)1.6.5 Latin America Molecular Scissors Technology Market Size YoY Growth (2015-2026)1.6.6 Middle East & Africa Molecular Scissors Technology Market Size YoY Growth (2015-2026)1.7 Coronavirus Disease 2019 (Covid-19): Molecular Scissors Technology Industry Impact1.7.1 How the Covid-19 is Affecting the Molecular Scissors Technology Industry

1.7.1.1 Molecular Scissors Technology Business Impact Assessment Covid-19

1.7.1.2 Supply Chain Challenges

1.7.1.3 COVID-19s Impact On Crude Oil and Refined Products1.7.2 Market Trends and Molecular Scissors Technology Potential Opportunities in the COVID-19 Landscape1.7.3 Measures / Proposal against Covid-19

1.7.3.1 Government Measures to Combat Covid-19 Impact

1.7.3.2 Proposal for Molecular Scissors Technology Players to Combat Covid-19 Impact 2 Molecular Scissors Technology Market Overview by Type2.1 Global Molecular Scissors Technology Market Size by Type: 2015 VS 2020 VS 20262.2 Global Molecular Scissors Technology Historic Market Size by Type (2015-2020)2.3 Global Molecular Scissors Technology Forecasted Market Size by Type (2021-2026)2.4 Cas92.5 TALENs and MegaTALs2.6 ZFN2.7 Others 3 Molecular Scissors Technology Market Overview by Type3.1 Global Molecular Scissors Technology Market Size by Application: 2015 VS 2020 VS 20263.2 Global Molecular Scissors Technology Historic Market Size by Application (2015-2020)3.3 Global Molecular Scissors Technology Forecasted Market Size by Application (2021-2026)3.4 Cell Line Engineering3.5 Animal Genetic Engineering3.6 Plant Genetic Engineering3.7 Others 4 Global Molecular Scissors Technology Competition Analysis by Players4.1 Global Molecular Scissors Technology Market Size (Million US$) by Players (2015-2020)4.2 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Molecular Scissors Technology as of 2019)4.3 Date of Key Manufacturers Enter into Molecular Scissors Technology Market4.4 Global Top Players Molecular Scissors Technology Headquarters and Area Served4.5 Key Players Molecular Scissors Technology Product Solution and Service4.6 Competitive Status4.6.1 Molecular Scissors Technology Market Concentration Rate4.6.2 Mergers & Acquisitions, Expansion Plans 5 Company (Top Players) Profiles and Key Data5.1 Cibus5.1.1 Cibus Profile5.1.2 Cibus Main Business and Companys Total Revenue5.1.3 Cibus Products, Services and Solutions5.1.4 Cibus Revenue (US$ Million) (2015-2020)5.1.5 Cibus Recent Developments5.2 Thermo Fisher Scientific, Inc.5.2.1 Thermo Fisher Scientific, Inc. Profile5.2.2 Thermo Fisher Scientific, Inc. Main Business and Companys Total Revenue5.2.3 Thermo Fisher Scientific, Inc. Products, Services and Solutions5.2.4 Thermo Fisher Scientific, Inc. Revenue (US$ Million) (2015-2020)5.2.5 Thermo Fisher Scientific, Inc. Recent Developments5.3 Merck5.5.1 Merck Profile5.3.2 Merck Main Business and Companys Total Revenue5.3.3 Merck Products, Services and Solutions5.3.4 Merck Revenue (US$ Million) (2015-2020)5.3.5 Recombinetics Recent Developments5.4 Recombinetics5.4.1 Recombinetics Profile5.4.2 Recombinetics Main Business and Companys Total Revenue5.4.3 Recombinetics Products, Services and Solutions5.4.4 Recombinetics Revenue (US$ Million) (2015-2020)5.4.5 Recombinetics Recent Developments5.5 Sangamo Therapeutics5.5.1 Sangamo Therapeutics Profile5.5.2 Sangamo Therapeutics Main Business and Companys Total Revenue5.5.3 Sangamo Therapeutics Products, Services and Solutions5.5.4 Sangamo Therapeutics Revenue (US$ Million) (2015-2020)5.5.5 Sangamo Therapeutics Recent Developments5.6 Editas Medicine5.6.1 Editas Medicine Profile5.6.2 Editas Medicine Main Business and Companys Total Revenue5.6.3 Editas Medicine Products, Services and Solutions5.6.4 Editas Medicine Revenue (US$ Million) (2015-2020)5.6.5 Editas Medicine Recent Developments5.7 Precision BioSciences5.7.1 Precision BioSciences Profile5.7.2 Precision BioSciences Main Business and Companys Total Revenue5.7.3 Precision BioSciences Products, Services and Solutions5.7.4 Precision BioSciences Revenue (US$ Million) (2015-2020)5.7.5 Precision BioSciences Recent Developments5.8 Intellia Therapeutics, Inc.5.8.1 Intellia Therapeutics, Inc. Profile5.8.2 Intellia Therapeutics, Inc. Main Business and Companys Total Revenue5.8.3 Intellia Therapeutics, Inc. Products, Services and Solutions5.8.4 Intellia Therapeutics, Inc. Revenue (US$ Million) (2015-2020)5.8.5 Intellia Therapeutics, Inc. Recent Developments5.9 Caribou Biosciences, Inc5.9.1 Caribou Biosciences, Inc Profile5.9.2 Caribou Biosciences, Inc Main Business and Companys Total Revenue5.9.3 Caribou Biosciences, Inc Products, Services and Solutions5.9.4 Caribou Biosciences, Inc Revenue (US$ Million) (2015-2020)5.9.5 Caribou Biosciences, Inc Recent Developments5.10 Cellectis5.10.1 Cellectis Profile5.10.2 Cellectis Main Business and Companys Total Revenue5.10.3 Cellectis Products, Services and Solutions5.10.4 Cellectis Revenue (US$ Million) (2015-2020)5.10.5 Cellectis Recent Developments 6 North America Molecular Scissors Technology by Players and by Application6.1 North America Molecular Scissors Technology Market Size and Market Share by Players (2015-2020)6.2 North America Molecular Scissors Technology Market Size by Application (2015-2020) 7 Europe Molecular Scissors Technology by Players and by Application7.1 Europe Molecular Scissors Technology Market Size and Market Share by Players (2015-2020)7.2 Europe Molecular Scissors Technology Market Size by Application (2015-2020) 8 China Molecular Scissors Technology by Players and by Application8.1 China Molecular Scissors Technology Market Size and Market Share by Players (2015-2020)8.2 China Molecular Scissors Technology Market Size by Application (2015-2020) 9 Rest of Asia Pacific Molecular Scissors Technology by Players and by Application9.1 Rest of Asia Pacific Molecular Scissors Technology Market Size and Market Share by Players (2015-2020)9.2 Rest of Asia Pacific Molecular Scissors Technology Market Size by Application (2015-2020) 10 Latin America Molecular Scissors Technology by Players and by Application10.1 Latin America Molecular Scissors Technology Market Size and Market Share by Players (2015-2020)10.2 Latin America Molecular Scissors Technology Market Size by Application (2015-2020) 11 Middle East & Africa Molecular Scissors Technology by Players and by Application11.1 Middle East & Africa Molecular Scissors Technology Market Size and Market Share by Players (2015-2020)11.2 Middle East & Africa Molecular Scissors Technology Market Size by Application (2015-2020) 12 Molecular Scissors Technology Market Dynamics12.1 Industry Trends12.2 Market Drivers12.3 Market Challenges12.4 Porters Five Forces Analysis 13 Research Finding /Conclusion 14 Methodology and Data Source 14.1 Methodology/Research Approach14.1.1 Research Programs/Design14.1.2 Market Size Estimation14.1.3 Market Breakdown and Data Triangulation14.2 Data Source14.2.1 Secondary Sources14.2.2 Primary Sources14.3 Disclaimer14.4 Author List

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Excerpt from:

Trending Now: Molecular Scissors Technology Market Detailed Analysis of Current Industry Figures With Forecasts Growth by 2026| Cibus, Thermo Fisher...

Longer Looks: Interesting Reads You Might Have Missed – Kaiser Health News

Each week, KHN finds longer stories for you to sit back and enjoy. This week's selections include stories on COVID, eating disorders, PTSD, the art of play, mosquitoes and more.

Politico:Can America Benefit From Covid? Ask 14th-Century FlorenceThe Covid pandemic has wreaked havoc on the U.S. economy. Around 33 million unemployment claims have been made, and hunger stalks millions more Americansand thats aside from the ravages from the disease itself.Yet big disruptions can bring big opportunities. Thinkers have already been considering how the world could emerge better, or smarter, from the Covid plague. And theres real historical precedent for this: The Italian Renaissance may have begun before the 14th-century plague known as the Black Death, but theres a strong case the diseasein both its ravages and the social changes it enabledhelped accelerate its progress, especially in the city of Florence. For a time, Florences economy bounced back with remarkable social mobility, and it became Europes premier center of artistic, cultural and scientific creativity. (Soll, 7/25)

Politico:How Covid-19 Could Give Kim Jong Un A Doomsday WeaponNorth Korea recently surprised the world by announcing it is developing a Covid-19 vaccine, joining a high-stakes race to show off its scientific chops. But experts increasingly believe the famously secretive Kim Jong Un could also have a more nefarious goal in mind: Using the humanitarian crisis to beef up his biological weapons arsenal. North Korea could use this legitimate vaccine aspiration as a way to enhance their biotechnology capability, says Andrew Weber, who was assistant secretary of Defense for nuclear, chemical and biological defense programs during the Obama administration. They could buy equipment from Western or Chinese sources that would be necessary for their vaccine effort, and then next year they could turn around and use it to produce biological weapons. (Ralph, 7/28)

The Wall Street Journal:Foods That Battle Stress During The Coronavirus PandemicAre you anxious? Angry? Feeling depressed?Consider what you eat. For more than a decade, studies have shown that a healthy diethigh in fruits, vegetables, whole grains, fish and other lean proteincan help fight depression. Now, emerging research in the nascent field of nutritional psychiatry suggests that certain foods can help manage a broader range of emotional challenges, such as anxiety, anger and insomnia. And while the most established treatments for mental-health conditions such as depression remain antidepressants and talk therapy, researchers say food can also be a very useful tool. (Bernstein, 7/27)

The Washington Post:Covid-19 Lockdown Nostalgia: It Was A Scary Time, But I Will Miss Our Enforced Family Togetherness.I sent a text to an old college friend in April, inquiring how she was faring under the covid-19 stay-at-home order then in place, and I confided in her that Id be sad to see it end. I liked that everything had slowed down, that for a brief time, Id stepped off the conveyor belt Id been on that made my life feel less meaningful. My friend, a 57-year-old writer in New York, wrote back immediately: Wow. Will not be sad when its over. Its a dark cloud hanging over life, and I feel panicked and dread for people in the restaurant industry, tourism, etc., and the domino effect that will have on us all." (Chesler, 7/26)

The New York Times:I Was A Screen Time Expert. Then The Coronavirus Happened.Before the pandemic, I was a parenting expert. It was a cushy gig. In 2019, I boarded 34 flights. I checked into nice hotels, put on makeup and fitted jewel-toned dresses, strode onto stages large and dinky, and tried to project authoritative calm. I told worried parents about the nine signs of tech overuse, like ditching sleep for screens. I advised them to write a family media contract and trust, but verify, their tweens doings online. While I was on the road, my two daughters were enjoying modest, cute little doses of Peppa Pig and Roblox, in between happily attending school, preschool, after-school activities and play dates, safe in the care of their father, grandmother and our full-time nanny. Now, like Socrates, I know better. I know that I know nothing. (Kamenetz, 7/27)

And other good reads

The New York Times:With Eating Disorders, Looks Can Be DeceivingAppearances, as Im sure you know, can be deceiving. In one all-too-common example, adolescents and young adults with disordered eating habits or outright eating disorders often go unrecognized by both parents and physicians because their appearance defies common beliefs: they dont look like they have an eating problem. One such belief is that people with anorexia always look scrawny and malnourished when in fact they may be of normal weight or even overweight, according to recent research at the University of California, San Francisco. (Brody, 7/27)

The New York Times:Me, My Relationship And PTSDSam and I began the conversation partly in jest. His co-worker had just eloped in Hawaii, and as we scrolled through their photos I gave him an elbow to the ribs and said in a singsong voice, Well, maybe we should go to Hawaii, too! Later we spoke about it in more thoughtful tones, and as it turned out, neither of us had ever been and we both had always wanted to go to Hawaii. I raised my eyebrows and widened my grin. I think we should do it. Not because its time to get married, I added, loudly. But because we have the perfect opportunity to do it. (Conner, 7/25)

The New York Times:The Way We Used To PlayAs kids, my seven siblings and I would run around outside under the night sky, the summer-hard soles of our bare feet the only shoes we needed, playing a game we made up called War. I grew up as one of a legion of kids living in Cedar Hills, Texas. We were also home schooled, so we were weird, and my world was made up of home and church. But in the evening we would play with the neighborhood kids, the ones with backpacks and clean shoes who waved to us on their way to and from school every day. (Lenz, 7/21)

The Atlantic:The Teaching That Works for Traumatized StudentsWhen Ben started flipping desks in the classroom, his teacher Heather Boyle ushered the rest of her first-grade class into the hallway for safety. Things had begun to unravel a few moments earlier, when Benwhose real name isnt being used, to protect his privacystruggled with a math lesson. He crawled under desks, bumping into other childrens legs. When his classmates complained, Boyle asked him to come out. I dont know how to do this stupid math, he screamed. (McKenna, 7/28)

Arizona Republic:The Navajo Nations Wait For Water Persists With Few AnswersThe line forms at the water spigotbefore dawn. In Chevrolets, Fords and Toyotas, men and women of all ages pull up, the beds of their pickups holding plastic tanks and barrels. Each day, all day long, people wait to take the white hose and let the water run into their tanks. Its the only reliable source of clean drinking water they can count on in this part of the Navajo Nation, and they come from miles around to fill up. (James, 7/28)

The New York Times:Why Some Mosquitoes Prefer HumansMosquitoes have been called the deadliest animal in the world: tiny creatures so dangerous that genetic engineering may be necessary to win the battle against them. But not all mosquitoes are equally responsible for devastating the human population by spreading disease. Out of thousands of species, only a few like to bite humans and even within the same species, mosquitoes from different places can have different preferences. Why do some find us irresistible, while others remain unimpressed? To answer that question, a team of Princeton researchers, working with a large network of local collaborators, spent three years driving around sub-Saharan Africa collecting the eggs of Aedes aegypti mosquitoes, which are responsible for Zika, yellow fever and dengue. (Chen, 7/23)

The rest is here:

Longer Looks: Interesting Reads You Might Have Missed - Kaiser Health News

BRAVE NEW WORLD IS (STILL) HERE – Norwich Radical

By Molly Ellen Pearson

CW: sexual assault, rape

David Wieners TV adaptation of Huxleys classic dystopia launched on Sky One and Peacock on July 15th 2020.

Set in New London in a society where class is enforced by genetic engineering and hypnopaedic indoctrination, the use of the euphoric drug soma is universal, public orgies are wholesome fun and mother is a swear word Brave New World is a novel with many themes. One of them is misogyny and the mechanisms by which it is expressed and perpetuated. Consequently, the portrayal of the novels central female character, Lenina Crowne, and her relationship with John the Savage (the emotional core of the story) are huge contributing factors to the success or failure of any adaptation. Wiener faces the challenge of depicting a society he describes as hugely problematic without condoning it, which raises questions about how the problematic aspects of the novel could, or even should be, adapted.

the challenge of depicting a society he describes as hugely problematic without condoning it

The events of Brave New World take place in 2540CE, but despite the many technological advances of New London, the treatment of women hasnt changed much since Huxleys time or ours. Beneath this brave new worlds veneer of equality, Huxley makes it plain that misogyny is alive and well. Secretaries are unanimously female with lustrous smiles, and are ordered about by powerfully built broad-shouldered men. In one scene two female characters discuss being patted on the behind by their boss, and the sexual assault is accepted as conventional male behaviour. In the opening scene a group of students tour the Hatchery where genetic engineering takes place, and it is made clear by the narration that there are no women amongst them.

Scientists make derisive comments about freemartins (women who have been genetically sterilised in utero with male sex hormone), mocking their tendency to grow beards. Women are subjected to compulsory Pregnancy Substitutes from the age of twenty-one, and those with especially wide pelvises are encouraged to begin having them as teenagers. The word father [is considered] not so much obscene as [mother] with its connotation of something at one remove from the loathsomeness and moral obliquity of child-bearing.

Alexis Soloski, writing for The New York Times, describes Lenina in the novel as a cheerful sex bunny and certainly this is the socially-sanctioned persona she adopts. Yet behind it, Huxleys Lenina is fully aware of the ugliness and meaninglessness of her world. At one point in the novel she recalls waking in the night as a child and hearing with a shock of fear the hypnopaedic suggestions that psychologically condition all citizens, the whispering that haunted all her sleeps. Like the prominent male characters in the story, she is deeply unhappy. But where they feel entitled to complain, to rail against the system, to riot, to write transgressive poetry, to request a transfer to the Falklands, Lenina takes soma and does what is expected of her with a determined smile on her face. For women, this is a familiar and well-indoctrinated message you are powerless, so you had better grit your teeth and just get on with it.

Soloski refers to Huxleys John, with considerably more accuracy, as prissy and deeply neurotic, anti-sex and anti-fun. This is, if anything, a generous assessment. Johns behaviour towards Lenina is characteristic of an abusive relationship. His attitude towards her swings between idealisation and devaluation in a manner characteristic of clinical narcissism. He slut-shames her for watching the immersive porn that is New Londons main form of entertainment (I dont think you ought to see things like that). He is controlling, condescending and physically violent. And yet worryingly, Ehrenreich, who plays John in Wieners adaptation, describes him as a man driven by his ardent belief in a deep, emotional love. At the climax of the novel, John beats Lenina to death for perceived unchastity (and, its implied, rapes her corpse). One wonders how such a statement and such a scene can possibly be reconciled.

Adapting a novel about a society whose bigotry you are unwilling to address, or even acknowledge, misses the point

In the novel, Johns treatment of Lenina is chilling because it is realistic. He is not the first man to feel entitled to a womans chastity; to objectify her, then subject her to physical and verbal abuse because she does not live up to his idealised fantasy. Nor is he the first misogynist to use literature to justify his Madonna-Whore complex (it is no accident that, of all the Shakespeare plays John reads, the most frequently referenced in the novel is Othello). Nor will he be the first to be romanticised because of it.

Dystopia is a vehicle to examine the sociopolitical injustices of our own time. Adapting a novel about a society whose bigotry you are unwilling to address, or even acknowledge, misses the point, resulting in an adaptation that colludes rather than condemns. The treatment of women in Brave New World is hugely problematic for a reason one that this adaption has seemingly decided to gloss over by reframing abuse as deep, emotional love.

Featured image Peacock

The Norwich Radical is non-profit and run by volunteers. All funds raised help cover the maintenance costs of our website, as well as contributing towards future projects and events. Please consider making a small contribution to fund a better media future.

Like Loading...

Related

Visit link:

BRAVE NEW WORLD IS (STILL) HERE - Norwich Radical

Trending Now: CRISPR-Based Therapeutics Market In-Depth Analysis Of Competitive Landscape, Executive Summary, Development Factors 2026|, Caribou…

LOS ANGELES, United States: QY Research has recently published a report, titled Global and China CRISPR-Based Therapeutics Market Size, Status and Forecast 2020-2026. The research report gives the potential headway openings that prevails in the global market. The report is amalgamated depending on research procured from primary and secondary information. The global Global and China CRISPR-Based Therapeutics market is relied upon to develop generously and succeed in volume and value during the predicted time period. Moreover, the report gives nitty gritty data on different manufacturers, region, and products which are important to totally understanding the market.

Key Companies/Manufacturers operating in the global Global and China CRISPR-Based Therapeutics market include: , Caribou Biosciences, Addgene, CRISPR THERAPEUTICS, Merck KGaA, Mirus Bio LLC, Editas Medicine, Takara Bio USA, Thermo Fisher Scientific, Horizon Discovery Group, Intellia Therapeutics, GE Healthcare Dharmacon

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/2027764/global-and-china-crispr-based-therapeutics-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Global and China CRISPR-Based Therapeutics market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Global and China CRISPR-Based Therapeutics Market Segment By Type:

Genome EditingGenetic EngineeringgRNA Database/Gene LibrarCRISPR PlasmidHuman Stem CellsGenetically Modified Organisms/CropsCell Line Engineering CRISPR-Based Therapeutics

Global Global and China CRISPR-Based Therapeutics Market Segment By Application:

Biotechnology CompaniesPharmaceutical CompaniesAcademic InstitutesResearch and Development Institutes Based on

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Global and China CRISPR-Based Therapeutics market.

Key companies operating in the global Global and China CRISPR-Based Therapeutics market include , Caribou Biosciences, Addgene, CRISPR THERAPEUTICS, Merck KGaA, Mirus Bio LLC, Editas Medicine, Takara Bio USA, Thermo Fisher Scientific, Horizon Discovery Group, Intellia Therapeutics, GE Healthcare Dharmacon

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/2027764/global-and-china-crispr-based-therapeutics-market

TOC

1 Report Overview1.1 Study Scope1.2 Market Analysis by Type1.2.1 Global CRISPR-Based Therapeutics Market Size Growth Rate by Type: 2020 VS 20261.2.2 Genome Editing1.2.3 Genetic Engineering1.2.4 gRNA Database/Gene Librar1.2.5 CRISPR Plasmid1.2.6 Human Stem Cells1.2.7 Genetically Modified Organisms/Crops1.2.8 Cell Line Engineering1.3 Market by Application1.3.1 Global CRISPR-Based Therapeutics Market Share by Application: 2020 VS 20261.3.2 Biotechnology Companies1.3.3 Pharmaceutical Companies1.3.4 Academic Institutes1.3.5 Research and Development Institutes1.4 Study Objectives1.5 Years Considered 2 Global Growth Trends2.1 Global CRISPR-Based Therapeutics Market Perspective (2015-2026)2.2 Global CRISPR-Based Therapeutics Growth Trends by Regions2.2.1 CRISPR-Based Therapeutics Market Size by Regions: 2015 VS 2020 VS 20262.2.2 CRISPR-Based Therapeutics Historic Market Share by Regions (2015-2020)2.2.3 CRISPR-Based Therapeutics Forecasted Market Size by Regions (2021-2026)2.3 Industry Trends and Growth Strategy2.3.1 Market Trends2.3.2 Market Drivers2.3.3 Market Challenges2.3.4 Market Restraints 3 Competition Landscape by Key Players3.1 Global Top CRISPR-Based Therapeutics Players by Market Size3.1.1 Global Top CRISPR-Based Therapeutics Players by Revenue (2015-2020)3.1.2 Global CRISPR-Based Therapeutics Revenue Market Share by Players (2015-2020)3.2 Global CRISPR-Based Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.3 Players Covered: Ranking by CRISPR-Based Therapeutics Revenue3.4 Global CRISPR-Based Therapeutics Market Concentration Ratio3.4.1 Global CRISPR-Based Therapeutics Market Concentration Ratio (CR5 and HHI)3.4.2 Global Top 10 and Top 5 Companies by CRISPR-Based Therapeutics Revenue in 20193.5 Key Players CRISPR-Based Therapeutics Area Served3.6 Key Players CRISPR-Based Therapeutics Product Solution and Service3.7 Date of Enter into CRISPR-Based Therapeutics Market3.8 Mergers & Acquisitions, Expansion Plans 4 CRISPR-Based Therapeutics Breakdown Data by Type (2015-2026)4.1 Global CRISPR-Based Therapeutics Historic Market Size by Type (2015-2020)4.2 Global CRISPR-Based Therapeutics Forecasted Market Size by Type (2021-2026) 5 CRISPR-Based Therapeutics Breakdown Data by Application (2015-2026)5.1 Global CRISPR-Based Therapeutics Historic Market Size by Application (2015-2020)5.2 Global CRISPR-Based Therapeutics Forecasted Market Size by Application (2021-2026) 6 North America6.1 North America CRISPR-Based Therapeutics Market Size (2015-2026)6.2 North America CRISPR-Based Therapeutics Market Size by Type (2015-2020)6.3 North America CRISPR-Based Therapeutics Market Size by Application (2015-2020)6.4 North America CRISPR-Based Therapeutics Market Size by Country (2015-2020)6.4.1 United States6.4.2 Canada 7 Europe7.1 Europe CRISPR-Based Therapeutics Market Size (2015-2026)7.2 Europe CRISPR-Based Therapeutics Market Size by Type (2015-2020)7.3 Europe CRISPR-Based Therapeutics Market Size by Application (2015-2020)7.4 Europe CRISPR-Based Therapeutics Market Size by Country (2015-2020)7.4.1 Germany7.4.2 France7.4.3 U.K.7.4.4 Italy7.4.5 Russia7.4.6 Nordic7.4.7 Rest of Europe 8 China8.1 China CRISPR-Based Therapeutics Market Size (2015-2026)8.2 China CRISPR-Based Therapeutics Market Size by Type (2015-2020)8.3 China CRISPR-Based Therapeutics Market Size by Application (2015-2020)8.4 China CRISPR-Based Therapeutics Market Size by Region (2015-2020)8.4.1 China8.4.2 Japan8.4.3 South Korea8.4.4 Southeast Asia8.4.5 India8.4.6 Australia8.4.7 Rest of Asia-Pacific 9 Japan9.1 Japan CRISPR-Based Therapeutics Market Size (2015-2026)9.2 Japan CRISPR-Based Therapeutics Market Size by Type (2015-2020)9.3 Japan CRISPR-Based Therapeutics Market Size by Application (2015-2020)9.4 Japan CRISPR-Based Therapeutics Market Size by Country (2015-2020)9.4.1 Mexico9.4.2 Brazil 10 Southeast Asia10.1 Southeast Asia CRISPR-Based Therapeutics Market Size (2015-2026)10.2 Southeast Asia CRISPR-Based Therapeutics Market Size by Type (2015-2020)10.3 Southeast Asia CRISPR-Based Therapeutics Market Size by Application (2015-2020)10.4 Southeast Asia CRISPR-Based Therapeutics Market Size by Country (2015-2020)10.4.1 Turkey10.4.2 Saudi Arabia10.4.3 UAE10.4.4 Rest of Middle East & Africa 11 Key Players Profiles11.1 Caribou Biosciences11.1.1 Caribou Biosciences Company Details11.1.2 Caribou Biosciences Business Overview11.1.3 Caribou Biosciences CRISPR-Based Therapeutics Introduction11.1.4 Caribou Biosciences Revenue in CRISPR-Based Therapeutics Business (2015-2020))11.1.5 Caribou Biosciences Recent Development11.2 Addgene11.2.1 Addgene Company Details11.2.2 Addgene Business Overview11.2.3 Addgene CRISPR-Based Therapeutics Introduction11.2.4 Addgene Revenue in CRISPR-Based Therapeutics Business (2015-2020)11.2.5 Addgene Recent Development11.3 CRISPR THERAPEUTICS11.3.1 CRISPR THERAPEUTICS Company Details11.3.2 CRISPR THERAPEUTICS Business Overview11.3.3 CRISPR THERAPEUTICS CRISPR-Based Therapeutics Introduction11.3.4 CRISPR THERAPEUTICS Revenue in CRISPR-Based Therapeutics Business (2015-2020)11.3.5 CRISPR THERAPEUTICS Recent Development11.4 Merck KGaA11.4.1 Merck KGaA Company Details11.4.2 Merck KGaA Business Overview11.4.3 Merck KGaA CRISPR-Based Therapeutics Introduction11.4.4 Merck KGaA Revenue in CRISPR-Based Therapeutics Business (2015-2020)11.4.5 Merck KGaA Recent Development11.5 Mirus Bio LLC11.5.1 Mirus Bio LLC Company Details11.5.2 Mirus Bio LLC Business Overview11.5.3 Mirus Bio LLC CRISPR-Based Therapeutics Introduction11.5.4 Mirus Bio LLC Revenue in CRISPR-Based Therapeutics Business (2015-2020)11.5.5 Mirus Bio LLC Recent Development11.6 Editas Medicine11.6.1 Editas Medicine Company Details11.6.2 Editas Medicine Business Overview11.6.3 Editas Medicine CRISPR-Based Therapeutics Introduction11.6.4 Editas Medicine Revenue in CRISPR-Based Therapeutics Business (2015-2020)11.6.5 Editas Medicine Recent Development11.7 Takara Bio USA11.7.1 Takara Bio USA Company Details11.7.2 Takara Bio USA Business Overview11.7.3 Takara Bio USA CRISPR-Based Therapeutics Introduction11.7.4 Takara Bio USA Revenue in CRISPR-Based Therapeutics Business (2015-2020)11.7.5 Takara Bio USA Recent Development11.8 Thermo Fisher Scientific11.8.1 Thermo Fisher Scientific Company Details11.8.2 Thermo Fisher Scientific Business Overview11.8.3 Thermo Fisher Scientific CRISPR-Based Therapeutics Introduction11.8.4 Thermo Fisher Scientific Revenue in CRISPR-Based Therapeutics Business (2015-2020)11.8.5 Thermo Fisher Scientific Recent Development11.9 Horizon Discovery Group11.9.1 Horizon Discovery Group Company Details11.9.2 Horizon Discovery Group Business Overview11.9.3 Horizon Discovery Group CRISPR-Based Therapeutics Introduction11.9.4 Horizon Discovery Group Revenue in CRISPR-Based Therapeutics Business (2015-2020)11.9.5 Horizon Discovery Group Recent Development11.10 Intellia Therapeutics11.10.1 Intellia Therapeutics Company Details11.10.2 Intellia Therapeutics Business Overview11.10.3 Intellia Therapeutics CRISPR-Based Therapeutics Introduction11.10.4 Intellia Therapeutics Revenue in CRISPR-Based Therapeutics Business (2015-2020)11.10.5 Intellia Therapeutics Recent Development11.11 GE Healthcare Dharmacon10.11.1 GE Healthcare Dharmacon Company Details10.11.2 GE Healthcare Dharmacon Business Overview10.11.3 GE Healthcare Dharmacon CRISPR-Based Therapeutics Introduction10.11.4 GE Healthcare Dharmacon Revenue in CRISPR-Based Therapeutics Business (2015-2020)10.11.5 GE Healthcare Dharmacon Recent Development 12 Analysts Viewpoints/Conclusions 13 Appendix13.1 Research Methodology13.1.1 Methodology/Research Approach13.1.2 Data Source13.2 Disclaimer13.3 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

See the rest here:

Trending Now: CRISPR-Based Therapeutics Market In-Depth Analysis Of Competitive Landscape, Executive Summary, Development Factors 2026|, Caribou...

Like Herpes, New Conspiracy Theories Erupt from Anti-Tech Activists – American Council on Science and Health

While much remains unknown about SARS-CoV-2, the novel coronavirus that causes COVID-19, we do know this: Like others before it, the new virus evolved naturally, perhaps in bats, before "jumping" into humans. A paper published in Nature Medicine explains that the genome of the virus strongly supports this narrative and that purposeful genetic engineering by humans is far-fetched.

No matter. The conspiracy lives. The Organic Consumers Association, which promotes the organic industry and is a top funder of the anti-GMO conspiracy website U.S. Right to Know (USRTK), just published an article that says:

Despite an ongoing cover-up by government authorities, the biotech industry, the military industrial complex and the mass media, there is growing scientific consensus that the COVID-19 virus was created and (most likely accidentally) leaked from a dual-use military/civilian lab in Wuhan, China.

Good grief. There are at least three conspiracies in that one sentence: (1) A massive cover-up; (2) the coronavirus was created; and (3) the Wuhan lab serves a military purpose. Let's debunk them one by one.

First, it is essentially impossible for there to be a cover-up involving the government, biotech industry, the military-industrial complex, and the mass media. A group that large would include tens of millions of people, and a study using mathematics alone shows how incredibly unlikely it is for that many conspirators to keep mum. Eventually, one of them would blow its cover.

Second, the claim that there is a "growing scientific consensus that the COVID-19 virus was created" is like saying that there is a growing consensus that Queen Elizabeth II is a shape-shifting lizard. To support itsridiculous claim, the Organic Consumers Association links to another conspiracy website.

Third, there is no evidence that the Wuhan virus laboratory is producing biological weapons (which is what is meant by "dual use military/civilian lab"). It's a biosafety level 4 (BSL-4) lab, similar to those at the CDC.

From One Conspiracy to Another

Fish gotta swim, birds gotta fly, and conspiracy theorists gotta theorize. When one conspiracy gets old, they move on to a new one. It's usually the same, predictable people, though.

Before it was interested in coronavirus conspiracies, the Organic Consumers Association was peddling all manner of nonsense, such as9/11 trutherism, chemtrails, FEMA's secret plan to implement martial law,pesticides causing school shootings, and (of course) anti-vaccine propaganda. Anti-tech activists posing as journalists, like Paul Thacker, have moved on from anti-GMO conspiracies to anti-5G ones. And a shocking number of Americans believe that Bill Gates wants to use vaccines to inject people with tracking devices. Your crazy uncle who said the moon landing was faked has moved on to more sinister theories.

Conspiracy Theories Are Like Herpes

We should think of conspiracy theories as "viruses of the mind." They are infectious because they spread from person to person. Like viruses, they are often completely impervious to treatment such as reason or logic. And once infected, a person holds on to conspiracy theories for life.

So basically, conspiracy theories are like herpes.

View original post here:

Like Herpes, New Conspiracy Theories Erupt from Anti-Tech Activists - American Council on Science and Health

Liberalism debate: How the FDP may be profitable once more WORLD – Pledge Times

FThe FDP is about everything in 2021. Party leader Christian Lindner has formulated the goal for the Bundestag election as to lead the liberals into the federal government. At the same time, the FDP must demonstrate its political relevance in no fewer than six state elections. In order to turn the weak poll values, Benedikt Brechtken, head of the Young Liberals in Recklinghausen, urged his party in a WELT contribution (Dare more liberal provocation) to show clear edges on three topics: capitalism, nuclear power, genetic engineering.

Capitalism, he writes, is the best and most social thing that has ever happened to mankind, due to the surge in prosperity it triggered. Genetic engineering in the form of golden rice can save up to two million lives annually. Nuclear energy contributes like no other energy source to the 1.5 degree target and is extremely safe, while coal energy kills many people.

An overheated housing market, millions of bonuses for scandalous managers and risky banking deals that are dragging entire economies into the abyss. Is the free market to blame for such excesses? WELT editor Moritz Seyffarth is investigating this question.

Source: WELT | kci, mgi, sey

Tactically, there is some reason to believe that, as a small party, you should adopt a strategy of maximum intensification. However, the provocation must also be reliable in terms of content. If you critically tap Brechtkens demands, they quickly collapse. So it was the unbridled casino capitalism (Hans-Werner Sinn) that plunged the world into the 2008 financial crisis. Many economies still suffer from the subsequent impoverishment.

The return to extremely costly nuclear energy is not even demanded by the energy industry itself, which has long since switched to renewables. Its worth taking a look at the topic of nuclear fusion, keyword ITER. And when it comes to green genetic engineering, even the Greens write in the draft of their new basic program that research in this field should be strengthened. Here too, the FDP is not waving a unique position. In short: the Brechtkensche Weg is a wrong way. The provocation fades away like a sparkler.

And yet the FDP has an urgent need to review its course, strategy, and canon of issues. The last state elections were disappointing, the federal government looks black and green, while personnel speculation is blowing around the Hans-Dietrich-Genscher-Haus. What has to happen

The FDP must recognize that the world has changed. You dont have to be a left-wing man to state that the gap between rich and poor has increased significantly. The resulting uncertainty in the population is deep. With Corona, this uncertainty continues to grow: people fear for their jobs, their pensions, their security. Questions about the resilience of society dominate the discussion.

also read

From a liberal perspective, freedom is the sense of politics (Hannah Arendt). The FDP should hold onto this compass without compromising. But it must add social aspects to its core of freedom: liberalism must become more inclusive and broaden its perspective.

Here are some suggestions. Christian Lindner personally should visit a nursing home and find out about the situation of the four million people in need of care in Germany. Conclusive concepts for improving our inefficient care system are urgently needed. Schoolchildren from immigrant families need special support so that they can fulfill their promise of advancement in our performance-oriented society. Here the FDP can set its own valuable accents.

In the tenant country Germany, tenants must be relieved of the fear of being kicked out of their four walls tomorrow. A policy approach that primarily favors investors and owners falls short. When it comes to poverty in old age, the recent decisions by the Union and the SPD are by no means convincing a huge opportunity for the FDP to reposition itself as an advocate for the older generation.

And finally: The demand to abolish the soli for the top ten percent has not been fitting since Corona at the latest. The state needs money, high earners dont really hurt the two or three thousand euros, while entrepreneurs can invest as a corporation at any time. To Benedikt Brechtken: No longer demanding the abolition of the soli for everyone that would be real liberal courage.

Hans Bellstedt (born 1963) is an entrepreneur, lecturer in political communication at the TU Berlin and a member of the FDP.

Hans Bellstedt

Source: Bellstedt

Read the original:

Liberalism debate: How the FDP may be profitable once more WORLD - Pledge Times

Biohacking Market: Rising demand for smart devices and effective drugs to drive the market – BioSpace

Global Biohacking Market: Overview

Experiments in the field of biology includes the use of drugs or gene editing or implants which improve the capabilities or qualities of living organisms. This is done by the individuals and their groups working in a scientific research environment or a traditional medical laboratory. Biohacking is managing one's own biology with the combination of nutritional, electronic, and medical technologies. It is also referred to as Do-It-Yourself (DIY) biology. Biohacking has brought out an absolute change in the field of synthetic biology. Biohacking have developed an urge of development and innovation of new products. It combines the aspects of technology and synthetic biology. Laboratory experiments are conducted scientists and research individuals to explore new avenues in biotechnology, genetic engineering, and molecular biology. Biohackers embark on numerous experimentations on the body such as monitoring of the heart rate or insertion of microchips to control the stress level. Biohackers have developed and are in the process of developing various products to explore the human body. Some of the remarkable products are smart drugs, microchips, magnetic fingertips, brain sensors, RFID implants, bacterial and yeast strains, body sensors, and smart blood pressure monitor health trackers. Currently, wearable analytic technological devices are available widely. The current generation is have a positive approach towards the Biohacking and its devices. Tracking of the heart rate, steps, blood sugar level, and movement of the body, burning calories or any other metrics, can be termed as Biohacking through analytics. The options in terms of Biohacking to keep track of ones biological performance are wide ranging, innovative, and ever growing.

Request Brochure of Report https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=63360

Global Biohacking Market: Key Trends

Increasing awareness about Biohacking, rising demand for smart devices and effective drugs, and growing prevalence of chronic diseases are factors expected to drive the global Biohacking market during the forecast period. However, strict regulations that govern the genetic engineering experiments, lack of funds required for research, and lack of expertise as well as cyber security practices are expected to restrain the market during the forecast period.

Request for Analysis of COVID19 Impact on Biohacking Market https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=63360

Global Biohacking Market: Segmentation

The global Biohacking market can be segmented based on type, product, application, end-user, and region. Based on type, the market can be divided into outside biohacking and inside biohacking. In terms of product, the global market can be classified into sensors, smart drugs, strains, and others. Based on application, the global Biohacking market can be segregated into synthetic biology, genetic engineering, forensic science, diagnosis & treatment, drug testing, and others. Based on end-user, the global Biohacking market can be divided into pharmaceutical & biotechnological companies, forensic laboratories, and others.

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=63360

Global Biohacking Market: Regional Analysis

In terms of region, the global Biohacking market can be segmented into North America, Asia Pacific, Europe, Latin America, and Middle East & Africa. North America is expected to be a prominent market for biohacking during the forecast period. The regions dominance can be attributed to strategic presence of key players in the U.S. and Canada.

Global Biohacking Market: Competitive Landscape

Key players operating in the global Biohacking market are Fitbit, Inc., Apple Inc, Synbiota, Inc., The ODIN, HVMN Inc, Thync Global Inc., Moodmetric, InteraXon Inc., and Behavioral Tech.

Pre book Biohacking Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=63360&ltype=S

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

ContactMr. Rohit BhiseyTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY - 12207United StatesUSA - Canada Toll Free: 866-552-3453Email: sales@transparencymarketresearch.comWebsite: https://www.transparencymarketresearch.com/

Read this article:

Biohacking Market: Rising demand for smart devices and effective drugs to drive the market - BioSpace

UK gene editing amendment withdrawn, but government commits to consultation – EURACTIV

An amendment tabled in the new UK agriculture bill, designed to allow access to new gene-editing technology, has been withdrawn but the government has pledged to conduct a public consultation on the issue, amid indications that it could eventually offer its support for the technology.

The amendment, withdrawn on Tuesday (28 July) after a lengthy debate in the House of Lords, has stirred up considerable debate in the past few weeks, both over environmental concerns as well as potential ramifications for the future agrifood trade relationship of the UK and the EU.

Despite the withdrawal of the bill, the decision is not quite clear cut just yet, as it does not technically prevent a similar or adapted amendment being reintroduced at a later stage.

However, there are indications that the UK government is not ready to offer its support for such an amendment right now, before the public consultation has been completed, but is generally looking favourably at gene editing, sources told EURACTIV.

A spokesperson for DEFRA [Department for Environment, Food and Rural Affairs] confirmed to EURACTIV that the government will carry out a public consultation before making any changes to the current approach.

They said that existing GMO regulations will remain in force through the EU Withdrawal Act, but declined to comment further on what exactly this consultation will entail.

However, the spokesperson stressed that organisms produced by modern mutagenesis techniques (such as gene editing) should not be subject to genetic modification regulation if the changes to their DNA could have occurred naturally or through traditional breeding methods.

The government recognises the opportunities precision breeding techniques could bring for farmers and the environment and remains committed to science-based policy and regulation of precision breeding techniques, such as gene editing, they said.

This standpoint echoes that of the UK National Farmers Union, who recently came out in favour of the technology.

The withdrawal of this amendment was welcomed by environmental groups, who have been fiercely campaigning against the amendment, which they warned could open the doors to a wide range of genetic engineering techniques.

The campaign group Beyond GM tweeted that this is a good outcome but warned that the government is still committed to deregulation and we must demand a more democratic and inclusive process.

Another UK umbrella campaign organisation, GM Freeze, added that they will be pressing for the consultation to be a meaningful in-depth consideration of public opinion and up to date science.

The amendment was staunchly defended by some members of the Lords, including Lord Krebs, who stressed the potential of the technology to make UK agriculture greener, more productive and more sustainable.

Baroness Hayman said she hoped that any future discussions on GMOs will be much more nuanced, seek to find common ground and be focused on the outcomes we are trying to achieve, rather than on very divisive attitudes.

She added she would argue that it is their responsibility to provide the appropriate regulatory framework for these advances, after what has been widely seen as the flawed ECJ judgment of 2018, referring to the European Court of Justice ruling that organisms obtained by new plant breeding techniques should, in principle, fall under the GMO Directive.

Baronness Young of Old Scone expressed concerns that rushing to deregulate gene editing to bring the UK into alignment with the US risks not being able to continue to do business with our major existing EU markets.

She added that it would be prudent to wait for the EU study on gene-editing, due to be published next April.

Beat Spth, director of agricultural biotechnology for EuropaBio, an influential biotech industry group, previously told EURACTIV that he hoped this amendment would offer an opportunity for a modernisation of the decades-old approach in view of ground-breaking new science, something he added is overdue both in the UK and in the EU.

With this move, the UK would send a strong signal to its leading public science institutions working on biotechnology and genome editing, he said.

[Edited by Zoran Radosavljevic]

The rest is here:

UK gene editing amendment withdrawn, but government commits to consultation - EURACTIV

BKS urges CM not to permit trials of Bt brinjal – The Hindu

TIRUCHI

The Bharatiya Kisan Sangh (BKS) has urged the Tamil Nadu Chief Minister not to give no-objection certificate for taking up field trials of Bt brinjal in the State.

To our surprise, the Genetic Engineering Appraisal Committee(GEAC) has recently granted permission to undertake Biosafety Research Level (BRL) - II tests of Bt brinjal, a genetically modified (GM) crop in your State. The trials are also allowed in some other States, N.S.Parthasarathy, State general secretary, BKS, said in a representation to Chief Minister Edappadi K.Palaniswami.

Condemning it as an unilateral decision of the committee, Mr.Parthasarathy sought to draw the attention of Mr. Palaniswami to the developments pertaining to the field trials of GM crops, including brinjal in the country.

There are several serious issues such as environmental pollution, human health, productivity and market monopolisation, which need to be addressed before allowing such trials of GM crops, Mr.Parthasarathy said.

Objections from almost stakeholders over the past few decades are yet to be satisfactorily answered. Furthermore, most of the prestigious institutions, including parliamentary standing committee, the technical expert committee of Supreme Court, views of eminent scientists and representatives from agriculturally important states have expressed their apprehensions over the trials. Many States have even banned GM food crops/ trials.

GAEC is party to the miserable failure of Bt cotton technology and illegal perpetuation of herbicide tolerant cotton. Under such circumstances the decision of GEAC is autocratic but also appears to be taken with some ulterior motive, he charged.

It was also sad that GAEC was trying to test GM crops in the field when the country was in the grip of the pandemic.

The BKS was raising awareness about the hazards of the technology and it is our earnest request to the Government not to allow the testing of GM crops in general and Bt Brinjal in particular within Tamil Nadu in the interest of entire farming community and consumers, Mr.Parthasarathy said and urged the Chief Minister to deny NOC to any agency for conducting field trials of GM crops and remain vigilant to check any unethical trials in the State.

You have reached your limit for free articles this month.

To get full access, please subscribe.

Already have an account ? Sign in

Show Less Plan

Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.

Move smoothly between articles as our pages load instantly.

Enjoy reading as many articles as you wish without any limitations.

A one-stop-shop for seeing the latest updates, and managing your preferences.

A select list of articles that match your interests and tastes.

We brief you on the latest and most important developments, three times a day.

*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.

See the original post here:

BKS urges CM not to permit trials of Bt brinjal - The Hindu

Have humans evolved beyond nature and do we even need it? – MENAFN.COM

(MENAFN - The Conversation) Our society has evolved so much, can we still say that we are part of Nature? If not, should we worry and what should we do about it? Poppy, 21, Warwick.

Such is the extent of our dominion on Earth, that the answer to questions around whether we are still part of nature and whether we even need some of it rely on an understanding of what we want as Homo sapiens. And to know what we want, we need to grasp what we are.

It is a huge question but they are the best. And as a biologist, here is my humble suggestion to address it, and a personal conclusion. You may have a different one, but what matters is that we reflect on it.

Perhaps the best place to start is to consider what makes us human in the first place, which is not as obvious as it may seem.

This article is part of Life's Big Questions The Conversation's new series, co-published with BBC Future, seeks to answer our readers' nagging questions about life, love, death and the universe. We work with professional researchers who have dedicated their lives to uncovering new perspectives on the questions that shape our lives.

Many years ago, a novel written by Vercors called Les Animaux dnaturs ('Denatured Animals') told the story of a group of primitive hominids, the Tropis, found in an unexplored jungle in New Guinea, who seem to constitute a missing link.

However, the prospect that this fictional group may be used as slave labour by an entrepreneurial businessman named Vancruysen forces society to decide whether the Tropis are simply sophisticated animals or whether they should be given human rights. And herein lies the difficulty.

Human status had hitherto seemed so obvious that the book describes how it is soon discovered that there is no definition of what a human actually is. Certainly, the string of experts consulted anthropologists, primatologists, psychologists, lawyers and clergymen could not agree. Perhaps prophetically, it is a layperson who suggested a possible way forward.

She asked whether some of the hominids' habits could be described as the early signs of a spiritual or religious mind. In short, were there signs that, like us, the Tropis were no longer 'at one' with nature, but had separated from it, and were now looking at it from the outside with some fear.

It is a telling perspective. Our status as altered or 'denatured' animals creatures who have arguably separated from the natural world is perhaps both the source of our humanity and the cause of many of our troubles. In the words of the book's author :

We will probably never know the timing of our gradual separation from nature although cave paintings perhaps contain some clues. But a key recent event in our relationship with the world around us is as well documented as it was abrupt. It happened on a sunny Monday morning, at 8.15am precisely.

The atomic bomb that rocked Hiroshima on August 6 1945, was a wake-up call so loud that it still resonates in our consciousness many decades later.

The day the 'sun rose twice' was not only a forceful demonstration of the new era that we had entered , it was a reminder of how paradoxically primitive we remained: differential calculus, advanced electronics and almost godlike insights into the laws of the universe helped build, well a very big stick. Modern Homo sapiens seemingly had developed the powers of gods, while keeping the psyche of a stereotypical Stone Age killer.

We were no longer fearful of nature, but of what we would do to it, and ourselves. In short, we still did not know where we came from, but began panicking about where we were going.

We now know a lot more about our origins but we remain unsure about what we want to be in the future or, increasingly , as the climate crisis accelerates , whether we even have one.

Arguably, the greater choices granted by our technological advances make it even more difficult to decide which of the many paths to take. This is the cost of freedom.

I am not arguing against our dominion over nature nor, even as a biologist, do I feel a need to preserve the status quo. Big changes are part of our evolution. After all, oxygen was first a poison which threatened the very existence of early life, yet it is now the fuel vital to our existence.

Similarly, we may have to accept that what we do, even our unprecedented dominion, is a natural consequence of what we have evolved into, and by a process nothing less natural than natural selection itself . If artificial birth control is unnatural, so is reduced infant mortality.

I am also not convinced by the argument against genetic engineering on the basis that it is 'unnatural'. By artificially selecting specific strains of wheat or dogs , we had been tinkering more or less blindly with genomes for centuries before the genetic revolution. Even our choice of romantic partner is a form of genetic engineering. Sex is nature's way of producing new genetic combinations quickly.

Even nature, it seems, can be impatient with itself.

Advances in genomics , however, have opened the door to another key turning point. Perhaps we can avoid blowing up the world, and instead change it and ourselves slowly, perhaps beyond recognition.

The development of genetically modified crops in the 1980s quickly moved from early aspirations to improve the taste of food to a more efficient way of destroying undesirable weeds or pests.

In what some saw as the genetic equivalent of the atomic bomb, our early forays into a new technology became once again largely about killing, coupled with worries about contamination. Not that everything was rosy before that. Artificial selection, intensive farming and our exploding population growth were long destroying species quicker than we could record them.

The increasing 'silent springs' of the 1950s and 60s caused by the destruction of farmland birds and, consequently, their song was only the tip of a deeper and more sinister iceberg. There is, in principle, nothing unnatural about extinction, which has been a recurring pattern (of sometimes massive proportions) in the evolution of our planet long before we came on the scene. But is it really what we want?

The arguments for maintaining biodiversity are usually based on survival, economics or ethics. In addition to preserving obvious key environments essential to our ecosystem and global survival, the economic argument highlights the possibility that a hitherto insignificant lichen, bacteria or reptile might hold the key to the cure of a future disease. We simply cannot afford to destroy what we do not know.

But attaching an economic value to life makes it subject to the fluctuation of markets. It is reasonable to expect that, in time, most biological solutions will be able to be synthesised, and as the market worth of many lifeforms falls, we need to scrutinise the significance of the ethical argument. Do we need nature because of its inherent value?

Perhaps the answer may come from peering over the horizon. It is somewhat of an irony that as the third millennium coincided with decrypting the human genome , perhaps the start of the fourth may be about whether it has become redundant.

Just as genetic modification may one day lead to the end of 'Homo sapiens naturalis' (that is, humans untouched by genetic engineering ), we may one day wave goodbye to the last specimen of Homo sapiens genetica. That is the last fully genetically based human living in a world increasingly less burdened by our biological form minds in a machine.

If the essence of a human, including our memories, desires and values, is somehow reflected in the pattern of the delicate neuronal connections of our brain (and why should it not?) our minds may also one day be changeable like never before.

And this brings us to the essential question that surely we must ask ourselves now: if, or rather when, we have the power to change anything, what would we not change?

After all, we may be able to transform ourselves into more rational, more efficient and stronger individuals. We may venture out further, have greater dominion over greater areas of space, and inject enough insight to bridge the gap between the issues brought about by our cultural evolution and the abilities of a brain evolved to deal with much simpler problems. We might even decide to move into a bodiless intelligence: in the end, even the pleasures of the body are located in the brain.

And then what? When the secrets of the universe are no longer hidden, what makes it worth being part of it? Where is the fun?

'Gossip and sex, of course!' some might say. And in effect, I would agree (although I might put it differently), as it conveys to me the fundamental need that we have to reach out and connect with others. I believe that the attributes that define our worth in this vast and changing universe are simple: empathy and love . Not power or technology, which occupy so many of our thoughts but which are merely (almost boringly) related to the age of a civilisation.

Like many a traveller, Homo sapiens may need a goal. But from the strengths that come with attaining it, one realises that one's worth (whether as an individual or a species) ultimately lies elsewhere. So I believe that the extent of our ability for empathy and love will be the yardstick by which our civilisation is judged. It may well be an important benchmark by which we will judge other civilisations that we may encounter, or indeed be judged by them.

There is something of true wonder at the basis of it all. The fact that chemicals can arise from the austere confines of an ancient molecular soup , and through the cold laws of evolution, combine into organisms that care for other lifeforms (that is, other bags of chemicals) is the true miracle.

Some ancients believed that God made us in 'his image'. Perhaps they were right in a sense, as empathy and love are truly godlike features, at least among the benevolent gods.

Cherish those traits and use them now, Poppy, as they hold the solution to our ethical dilemma. It is those very attributes that should compel us to improve the wellbeing of our fellow humans without lowering the condition of what surrounds us.

Anything less will pervert (our) nature.

To get all of life's big answers, join the hundreds of thousands of people who value evidence-based news by subscribing to our newsletter . You can send us your big questions by email at and we'll try to get a researcher or expert on the case.

More Life's Big Questions :

MENAFN3007202001990000ID1100564688

Original post:

Have humans evolved beyond nature and do we even need it? - MENAFN.COM

What Will It Take to Restore the American Chestnut Tree? – New Hampshire Public Radio

The giant American chestnut tree all but disappeared 70 years ago, killed by a blight that struck at the turn of the last century. By 1950, an estimated four billion of these magnificent trees were gone from our Eastern forests, and the tree, once dominant, is considered functionally extinct. We talk with researchers and volunteers who are working with promising new technologies to restore the American chestnut tree. There are still wild remnants of the tree in our forests - could you identify an American chestnut tree if you happened upon it?

Airdate: Tuesday, July 28, 2020

Listen to the conversation.

GUESTS:

This Granite Geek article in the Concord Monitor inspired us to look into American chestnut tree restoration:Breeding isn't resurrecting the chestnut tree; genetic engineering might.

Here's information from The American Chestnut Foundation:Why Bring Back the American Chestnut?

This transcript was machine-generated and contains errors.

Laura Knoy: From New Hampshire Public Radio, I'm Laura Knoy and this is The Exchange. The once dominant American chestnut all but disappeared 70 years ago, killed by blight that struck at the turn of the last century and despite many efforts to restore the trees since then, researchers have struggled to produce a blight resistant American chestnut. But now some are looking to new technology to turn this venerable tree's fortunes around. And today, on The Exchange, we ask, can we bring the American chestnut back?

Laura Knoy: Our guests are Kendra Collins, New England regional science coordinator for the American Chestnut Foundation. Also Thomas Klak, University of New England, professor of Environmental Sciences and vice president of the Foundation's Maine chapter, and Doug McLane, president of the Vermont/New Hampshire chapter and involved in local pollination efforts. And welcome to all of you. And Doug, I want to start with you. Why restore the American chestnut? What is it about this tree that makes it so great that you think it's worth all the effort?

Doug McLane: Boy, that's a that's a big question. And good morning, Laura. Nice to be here. The best analogy I can give to somebody is if we were trying to tell our grandchildren that we used to have a really cool tree called a Sugar Maple and it was beautiful and it gave sugar and if they nobody had ever seen a sugar maple, it would be hard to describe how grand it was. And the same with the American chestnut. Very few of us, anybody under 90 years old, has really never seen a good stand of wild American chestnut. So we have to go by the historical record that they were the most dominant tree in north eastern North America, the most dominant hardwood. And there are all kinds of reasons that I'm sure Tom and Kendra will go into. But there are hundreds of reasons for trying to bring back the American chestnut.

Laura Knoy: Well, and just remind us, Doug, how dominant it was. The descriptions are pretty remarkable.

Doug McLane: The most common and probably the best one is the range of American chestnut used to be from Maine to Georgia, and they said a squirrel could travel from Maine to Georgia on chestnut trees without ever touching the ground. There were approximately five billion trees that died, all within a period of one human generation.

Laura Knoy: And huge trees, right Doug, Like huge, huge around and wide wide canopies. Just to remind us how magnificent these trees were.

Doug McLane: Yeah, they were. They were called the redwoods of the East, although I think like most trees, probably most of them were what we would think of as a large oak tree. And some of them got massive with five and six foot diameter bases.But the main thing was that they were the most important food for the forest, mast food. And so they for that deer, turkey, bear, Native Americans, settlers and they're still delicious to eat. I think kind of the best way to someone's heart is often through their stomach and they are delicious.

Laura Knoy: Well, and Kendra you recently wrote a top ten reasons why the chestnut is worth restoring. In addition to what Doug said, what other reasons would you add, Kendra?

Kendra Collins: Well, the American chestnut is a great species for forest biodiversity. It's as Doug mentioned, it's a great species for wildlife. It provides shelter. It provides food. At different growth stages it provides different kinds of habitat. So getting these trees back into the forest would be really beneficial to eastern forests, especially in the face of so many other important tree species declining. This is a really hopeful effort from a human use standpoint. There's a lot of great uses for chestnuts, a great timber species that grows tall, straight up and limbless for the first 50 or so feet. So from a timber perspective, it's a dream. It's very rot resistant wood so a variety of uses there. Settlers used it for log cabins. Most of the tobacco barns you see in Connecticut are made out of chestnut, split rail fences in the Smokies are original chestnut. So it's a great timber species. You can also definitely get some great carbon sequestration benefit out of chestnuts, a long lived and fast growing hardwood. And from a reclamation standpoint, it can grow on pretty marginal sites. It's been used in the central Appalachians for a lot of mine land reclamation. But I think the biggest reason is just to show that we can save a tree species. There's a lot of other species in decline. The effort for chestnut has been ongoing for almost one hundred years now. And we're really seeing some hope at the end of the tunnel. And we're really looking to our story, too, to prop up some of these other species like ash and elm that are declining.

Laura Knoy: Well, I want to ask you all a little bit later about how your efforts to restore the chestnut might translate into efforts to save these other tree species that we all love in New England and that we hear are struggling as well. But what about the the tree's ability, Kendra, this is interesting to me, and I did not know this until yesterday, this particular tree's ability to survive and thrive in poor soils. Why is that so important right now, especially in the eastern United States?

Kendra Collins: Well, it gives us a lot of options for where to plant chestnuts, it's, you know, generates a more of a general species in terms of where it can survive. But as I mentioned, in the central Appalachians, it's been used quite a bit for mine land reclamation. So when you have these mine spoil sites that are generally just sort of a mineral substrate, kind of crushed up rocks, really, you can plant chestnuts and they will actually grow and help get a new forest going in these sites, which is a lot more beneficial to the environment, to the native species, than reclaiming it into, say, a grass field, which is often what is happening. So that would be the big, big one for me.

Laura Knoy: Tom, it's been said that the chestnut died out before we really had a chance to study and appreciate fully its ecological importance. But the famed forester Gifford Pinchot said he believed this tree's ecological importance was as impressive as the tree itself. That's a quote that you see a lot. What do we know, Tom, about the role that this tree used to play in forest ecosystems?

Tom Klak: Good morning, Laura. Nice to be on your show. Yeah, it was super important ecologically. The science of ecology was not as advanced back then as it is now. We know six species of moths went extinct when the chestnut suffered the blight because of the chestnut was their host plant. I'm sure there are many other relationships that got lost in the destruction of the blight, some of the studies that have been done lately to ensure --we'll get into this issue of the transgenic chestnut -- but studies have indicated when when tadpoles are fed chestnut leaves detritus, they do better than they do on other species that have replaced the chestnut like maple and beech. So it gives you a little bit of an indication of the richness of the forest that's been lost. They said that in some places, the chestnut burrs which contain the seeds would be one foot deep or more in the forest floor come October. So you can imagine the wildlife benefits of that. And no doubt that wildlife was much more abundant back when the chestnut thrived.

Laura Knoy: You know, give us a little bit more on that tadpole study, Professor Klak, because I think it does demonstrate what was lost in terms of forest health, which we're all told is so important right now, especially given climate change. Give us a little bit more on that tadpole studies, how the tadpoles were healthier eating the leaf litter of chestnut trees than other trees.

Tom Klak: Right. Yeah, so that connects us with why we were studying this, and it's our colleagues at State University of New York in Syracuse and the Environmental Science and Forestry College. So they have been testing in many different ways how the what we call the transgenic chestnut -- we'll talk more about that in a minute, that's the one that has the wheat gene inserted to give it blight tolerance -- how does it perform compared to the wild chestnut tree? And in all the studies, the evidence shows that it performs exactly the same. No difference. But a kind of surprisingly out of that work was the fact that the tadpoles actually did better on chestnuts, be they your wild chestnuts or the ones with the wheat gene inserted, which, again, was a revelation. It wasn't the point of the study, but it gives you a little bit of an indication of the important ecological relationships that we've lost and how the forest has suffered. Certainly they've suffered just from from not having the food of the chestnut in fall and into the winter. But there's many other things that I'm sure we're going to find out when we bring more and more chestnuts back.

Laura Knoy: Wow. I find that fascinating. Kendra, what does that suggest to you? Again, these tadpoles being a lot happier and healthier, I guess, eating chestnut left-over than maple or other type of leaf litter?

Kendra Collins: Well, I will admit, I am not a tadpole expert either, my background is in forestry and specifically American chestnut. But, you know, I think ecologically what that says to me is that this was a food source that was very abundant and available to these species of frogs and that they developed the ability to thrive with that food source.And having lost it, they found other species that they can eat. But having chestnut back might be might make them even happier.

Laura Knoy: Doug, I have to ask you a very basic question, and we're on the radio, so you're going to have to use your best descriptive skills. Would we recognize an American chestnut if we saw it?

Doug McLane: Boy, that's yeah, that's a great question. You certainly would if you belong to the American Chestnut Foundation. Well, my wife sometimes doesn't even like to drive in a car with me because I'm looking more at the trees for chestnut leaves than at the road. And it's a very distinctive leaf and a very distinctive shaped tree and also the fact that it's the very last native tree to flower. So they were just flowering a week and two weeks ago, long after the oaks and the elms and the maples have flowere. So it's fairly easy to pick out a wild American chestnut. But the sad reality is only one out of, whatever, ten thousand ever makes it to flowering stage. So you kind of have to look at the leaf and not for the flowers. And yeah, once word gets around, it's actually, it's a contradiction. We say there are very few chestnuts left. There are a lot of chestnuts growing out there. It's just that very few of them make it to the reproductive stage, which is what they would need to survive without human help.

Laura Knoy: So how far do they make it, Doug, like 10 years or 15 years?

Doug McLane: Oh, there are quite a lot of them that are 50 and 70 years old. There is a surprising number of large surviving American chestnuts. But the idiosyncrasy that they only reproduce, even though every tree has a male and female flowers on it, they only reproduce if there's a second tree fairly nearby. So the odds of having them grow into reproductive stage and having two of them close by is rare indeed.

Laura Knoy: Interesting. And you know, when I was a kid, we had a big, big chestnut tree in the backyard. But I'm guessing that was a different kind of chestnut. So there are other chestnuts, right? Like how can you tell the difference?

Doug McLane: Well, well, no. See, it's by name only. In other words, the horse chestnut is really not even related other than being a tree. But most people who work with horse chestnuts in their neighborhood and the burr looked very similar to the nuts that boys like to throw at each other and stuff are very similar looking. They're in inedible in a horse chestnut.They're very edible in an American chestnut. So really, most everyone that thinks they've seen a chestnut tree has seen a horse chestnut, which is an import from Europe, although the Buckeye from Ohio and areas like that is a native, a native. So, yeah, very few people have really seen a healthy big American chestnut tree.

Laura Knoy: Well, I want to remind our listeners that you can join us with your questions and stories about the American chestnut. That's what we're talking about today on The Exchange and the many, many efforts to restore these trees since they were not completely, but mostly wiped out in the last century. So all of you have made the case as to why it is worthwhile to restore this tree. And Kendra, that gets into the American Chestnut Foundation. When did this group get started and what's your approach now toward restoration?

Kendra Collins: Sure, so the American Chestnut Foundation is a little over thirty five years old, we were founded in 1983 and we were also lucky to piggyback off earlier chestnut restoration work, some other programs that had kind of gotten going and not quite made it as far as they had hoped. So we're the effort, I would say has been going on for about one hundred years, but our organization is a little over thirty five years old. Our initial approach was primarily a conventional breeding program, and since then technologies have advanced, scientific knowledge is advanced, and we've expanded that to this three pronged approach that we call 3BURR, which is the three B's are breeding, biocontrol and biotechnology, united for restoration, kind of a play on the fruit that the chestnut produces, which is a burr. It's very cute. And so our breeding work is conventional breeding. It is taking on at our Staff Research Farm in Meadowview, Virginia, as well as by our 16 state chapters throughout the native range. It's really how we get a lot of our work done is through our chapter programs. The biocontrol work is something we support but is done primarily by research partners in Maryland and West Virginia. And then the biotechnology work primarily encompasses the transgenic tree that Tom has mentioned. This was developed by Suny'S Environmental science and forestry school in Syracuse itself and the research team there led by Bill Powell. So those are kind of the three directions we're going. There's certainly a lot of overlap, especially between the breeding and biotechnology. Those biotech tools have really advanced recently. And so we are actually using a lot of biotechnology tools to better assess our breeding program and help us make any adjustments that we can to make that project, that piece of our work, more efficient and more successful.

Laura Knoy: So conventional breeding, most people know what that is, Kendra, we all learned about, you know, plants in high school biology, biocontrols, that's basically when you try to use another biological element to go after the blight. Is that right, Kendra?

Kendra Collins: That's what biocontrol is, yes. And the primary bio control option for chestnut or at least what's receiving the most attention and work is hypervirulence. And this is a case where there's a virus that actually reduces the virulence of the fungus and therefore makes it less pathogenic on the tree. And that just gives the tree a little bit of an edge and we're hoping enough of an edge that it can survive. So it's certainly a worthwhile avenue.

Laura Knoy: Well, and coming up, we'll talk about the third leg of what you mentioned, biotech. There's a lot going on there and sometimes it's controversial. I also want to let listeners know that we have an amazing old picture of these trees on our Web site that gives you a sense of just how huge they could be. Come check it out at NHPR.org/Exchange. Today, a new chapter in the long effort to restore the American chestnut. As we've heard, these giant trees once dominated Eastern forests, but since the 1950s, they've been considered functionally extinct. Now, though, some researchers feel they're closer than ever to restoration. After many decades. We're finding out more and hearing from you. What legends have you heard about these trees that were so important to Eastern ecosystems and communities? How much effort do you think should be made toward restoring them, given the many other challenges that our forests face? With us for the hour, Kendra Collins, New England regional science coordinator for the American Chestnut Foundation. Also Thomas Klak, University of New England Professor of Environmental Studies and vice president of the Foundation's Maine chapter, and Doug McLane, president of the Vermont/New Hampshire chapter, who's also actively involved in local pollination efforts. And Celia in Thornton is calling in. Hi, Celia. You're on the air. Thanks for being with us.

Caller: Hi. Good morning, Laura. I just happened to wake up very late this morning and heard your show and leapt out of bed and called right away. I live near the Welch-Dickey trailhead surrounded by National Forest in Thornton and five years ago when I worked for the, volunteered for the Squam Lake Science Center. I was given two seedlings of American horse chestnut or chestnut trees and told to plant them close to each other, which I did with no special attention. I now have two beautiful, maybe six feet tall trees close to each other that are doing very well, surrounded by the national forest. And I'm just wondering is a question for your expert, should I be doing anything to ensure there the fact that they will live and thrive for the next hundred years?

Laura Knoy: Wow. It's great to hear from you, Celia. And I love that you jumped out of bed and gave us a call. And Doug McLane, I'm going to throw that to you, please.

Well, that's fascinating for a lot of reasons. I hike the Welch-Dickey trail myself. We all do. Planting trees in the wild, you have a pretty good chance that they will live a long time. But you also have to realize that pretty much every single American chestnut that's planted will die of the blight. The ones that survive to old age, and we have what we believe is the Vermont New Hampshire champion right near us here up in Rumney. And it's probably reached, I can't quite get my arms around the trunk, and it's probably that old because it's in the edge of the blight range. And so there's not a lot of blight pressure. So to answer the question of what can you do to help your trees, as long as they have good sunlight, that's the most important thing. And I think you're off and running. Those trees will be fun to watch grow. Just don't be too disappointed if they do get the blight, because there's hope on the way with the work that the foundation is doing, we hope to be able to pass out blight resistant nuts in our lifetime.

Laura Knoy: Ok, so just to clarify then, it isn't that this tree completely died out. There are individual success stories, but they're fragile, Doug, is that it?

Doug McLane: Well, here's here's the contradiction. And it's a hard one to wrap your arms around. The blight does not kill anything in the soil. So the blight does not kill the whole tree. It kills what's above the ground. But the chestnut has a tremendous ability to re-sprout. So most of the chestnuts and here's a number that I think is amazing. There are an estimated three to four hundred million surviving American chestnuts east of the Mississippi. Most of them are re-sprouted from old trunks that died when the blight hit over one hundred years ago. So that the tenacity of the tree is amazing. I was hiking at the Appalachian Trail years ago down in North Carolina, and I saw chestnut trees all day, but most of them in the one to two inch range. They just very seldom get big before the blight hits them. So the genetic diversity is out there. But what isn't out there...it's a little bit like somebody who saw the last surviving passenger pigeon in the world in the Cincinnati Zoo in the early 90s and hundreds, the species wasn't extinct but was doomed to extinction. So it's a little bit like the American chestnut. It's not extinct, but it's not able to overcome the blight without some human help.

Laura Knoy: Ok, well, Celia great to hear from you. And let's take David in Canterbury. Hi, David. You're on the air. Welcome.

Caller: Hey, good morning. Boy, I love these kind of shows. I have two native. I was cutting firewood and I saw those chestnuts. The two of them are approximately four or four and a half inches high. They're going up 20, 25 feet tall. And I'm wondering what I can do. I thought, I had chickens with composted chicken manure put around to root out the drip line, help to boost their immunity to is there anything you can put into soil that will help them?

Laura Knoy: Wow. And I love this question. Kind of relates to Celia was saying, what can I do to help these, you know, these few remaining trees survive? Kendra, do you want to jump in?

Kendra Collins: Yes, sure. You know, I don't think that fertilizing them is going to help with immunity, but certainly chicken manure is going to have a lot of nitrogen. Chesnut eats up nitrogen. So if you wanted to grow fast, go for it. They would appreciate a little snack. The one tool for landowners that have chestnuts that they want to keep going. The assumption is that these are wild American chestnuts with no tolerance to the blight. So there's one tool you can kind of keep in your back pocket, and that's called mud packing. You can actually, if you monitor your trees for the presence of light cankers, which are fairly obvious, they'll look like sort of sunken damage spots on the stem of the tree. The fruiting bodies of the fungus are bright orange. So you'll see those, they are about the size of a pinhead, but you'll see a lot of them in those cankers and they they attack the living tissue under the bark and just work their way around whatever system they land on, whether that's the main trunk or a branch mud-packing, you can actually cut back that canker and put a mud compress on that area, wrap it in plastic, and it should kill an individual canker.

Kendra Collins: Now, this is a great tool if you catch the canker relatively early before it's girdled half the tree, you're not going to go mud-pack every tree in the forest. So it's not a solution for your organization to restore the species, but it can keep trees on your property going for a little bit longer.The only other thing I would add is that if anyone does have chestnut trees on their property, we would love to hear about them. One of the ways that we incorporate new trees in our program is by getting reports from landowners and interested citizens that might find them out hiking. We have some great resources on our website, ACF.org, for identifying the trees, for getting a form,for filling out a form to send in with a sample and all those to actually come to my office. And I'm always happy to look at more of them.

Laura Knoy: Well, and David and Celia, we always have links on our website to these resources. So you can go to our website as well. It's NHPR.org/Exchange. And again, check out the picture of these huge, huge chestnut trees from must be more than a hundred years ago that we've got there, too. It's pretty amazing. Thank you for calling in, David. And a couple of emails I'd like to share with you. Lee in Westmoreland says when are transgenic trees are likely to be available to buy at something like a garden center, I want to address that. And then Jeanne in Saco, Maine, writes in, should we be concerned about genetic engineering and its effects on the local environment with the chestnut restoration project? So two great comments from our emailers. And to you first, Tom, I know you've been working on some of this transgenic research at the University of New England. So to Lee's point first, when might transgenic trees be likely to be available?

Tom Klak: We we don't know that ourselves, because the decision is going to be made by three federal agencies that are evaluating the transgenic tree, so it's right now a regulated item. The argument, the petition, has been submitted to the particularly to the Department of Agriculture to get to the nonregulated status. So it's up to them to make a decision. It's worth noting that the USDA will soon have a public comment period where your listeners can can chime in about the transgenic chestnut. And we don't know exactly when that's going to happen, but USDA tells us it's going to be soon. So it has to go through the regulatory process and after that, then there will be opportunities for dissemination.

Laura Knoy: So before we get into the concern that Jeanne raises, and I have another email, too, that raises a similar concern. Just a little backdrop, please, Tom. So you mentioned earlier a wheat gene that scientists have been breeding into the American chestnut that seems to be working. This is after many years of traditional sort of crossbreeding or hybrid breeding with a Chinese chestnut tree did not work. Is that a correct summary, Tom?

Tom Klak: Yes. The we talked earlier about the importance of biotechnology in science in general and advancing our understanding and ability to deal with problems, especially a problem like this that we created. It's worth noting, why do we have why why has the most important tree of the eastern United States going functionally extinct? Well, we accidentally imported this lethal pathogen from Asia when people brought in the Japanese chestnut and the Chinese chestnut. So that's how it got here. So we need to think about, well, how do we reverse that? So what we've discovered with with biotech and Kendra mentioned this, we've been doing a lot of revealing work with genomics. And what that has revealed is that the Chinese chestnut tree, which has the ability to tolerate the fungal blight, it's a multiple gene process that allows the Chinese chestnut tree to tolerate the blight. Up until very recently in the genomic revelations, it was thought it was only two or three genes that mattered on the Chinese tree. Now we know it's many more genes than that. So that's the issue right now of how one would move a great number of genes from the Chinese tree over. The other approach, and this is the biotech approach, is to identify a single gene that can allow the American chestnut tree to tolerate the blight.

Laura Knoy: It turns off that that lack of resistance....Go ahead, Tom.

Tom Klak: Yes, it detoxifies the acid. The fungal blight uses an acid to kill the American chestnut. The fungal blight doesn't need to kill the American chestnut, an important thing, it can survive on other dead material in the soil. And it does. And survive on the bark of the Chinese chestnut, on the American chestnut, as it has for millions of years in Asia when it has coevolved with the Chinese chestnut. So what the wheat gene insertion into the chestnut does is allow it to tolerate the fungal blight, doesn't kill it. The fungal blight can happily reproduce and function without killing chestnut trees. And so that's the approach that my students and I have been working on at the University of New England.

Laura Knoy: So I think to you next, Doug, but also you Kendra, but you Doug. What about Jeanne's concern and I've heard this elsewhere, concern that genetic engineering will have harmful impacts on the local environment if you were able to do this genetically modified American chestnut tree and it took off and it thrived, there is concern that it might put some other unknown materials out in the wild. And I just wonder how you feel about that, Doug.

Doug McLane: Well, that's a big question, no pun intended, but I might go out on a limb a little bit on this and give you a personal reflection, which is that the people that are concerned about biotechnology, I think certainly have their hearts in the right place and I actually identify with that a lot. I don't think we should willy nilly just think that we should fool with genes and Mother Nature. I think the chestnut tree deserves a definite special exception because it's talking about a keystone species that will likely go extinct without some help. So to answer your question. There's really not a... the downside of biotechnology is that it simply doesn't work, that the tree is not able to go back into our forests and compete against the large hardwoods that it has to become again a dominant species. The danger is not that it will somehow run amok and pollute other trees. Chestnut spread very slowly. They were the last species to come back north after the glacier retreated. They don't have lots of seeds like elm tree or a maple tree. They have a very large nut that's easy to keep track of and control. So if it doesn't work, we'll have to go on to the next thing but right now it is the the best hope we have for saving the chestnut tree.

Laura Knoy: Well, Kendra, get your thoughts on that, too, after a short break. So coming up, we'll look more at new efforts to restore the American chestnut. This is The Exchange on NHPR.org. Today, the decades long effort to restore the American chestnut, why it matters to both ecosystems and communities and whether a new chapter is at hand. We're finding out more and we've been hearing from you. And Kendra, Tom and Doug, just before the break, we were talking about a concern raised by a listener who was worried about the possible impacts of a transgenic American chestnut, one that has used biotechnology to be resistant to this blight that wiped out this species. And Doug, in response, you said you were not concerned that these trees would, quote, unquote, pollute the forest. I did receive an email early this morning from Steve Taylor from the Stop GE Trees campaign. It's long, so I won't read the whole thing, Steve, but thank you for writing in. He says that chestnut restoration project under the direction of researcher William Powell intends to release a blight resistant American chestnut into wild forest ecosystems. He says corporate backers of Powell and the American Chestnut Foundation support use of the iconic American chestnut as a strategy to break through longtime public opposition to FE trees. In other words, genetically engineered trees. And there's a couple other points he makes. But that is the main point concerned that these trees would irreparably harm natural ecosystems and also that this is just an excuse, a sort of nose under the tent for more genetically modified plants and trees. And it's a big, big controversy and a big concern. And Kendra, I'm going to let you jump in on that.

Kendra Collins: Sure. So first, I'd like to correct just the assumption that big Ag or big business is behind this effort, that is absolutely not true. The lab at ESF has received funding primarily from from philanthropic sources. The tree is going to be in the public domain. The effort behind this is coming from a place of wanting to help and repair an ecosystem. That out of the way, the safety of this is something that the researchers at ESF have taken very seriously.

Laura Knoy: And sorry to interrupt, but ESF is what, just remind us again?

Kendra Collins: SUNY's Environmental Science and Forestry College in Syracuse. That's where this transgenic tree has been developed in Bill Powell's lab.

Laura Knoy: SUNY is the State University of New York. Go ahead.

Kendra Collins: Yes. And the ESF.edu/chestnut website is great, if any listeners have questions or are interested to learn more about their project, they've got a lot of great information up. The gene from wheat was selected in part because it was assumed it would be effective at preventing the blight from killing the chestnut, but also because it had been shown to be relative or very safe. It's from wheat. It's in a lot of other plants that are already in the ecosystem that are consumed by humans on a regular basis. So it's not nearly as, scary, I guess, as others they could have chosen for folks who are a little uncomfortable with the technology, but they've also done a really great job of testing these transformed trees in comparison with wild type chestnuts for their partnerships with mycorrhizal fungi, for their tadpole feeding, for bee feeding on pollen, for a variety of things that would be stand-ins for how these trees would perform in the forest. Deregulation is actually really important for being able to test these trees. At this point anyone who wants to plant transgenic chestnuts has to do it under permitted conditions, which are pretty limiting. To be able to test these things on the landscape the deregulation is actually going to really be helpful, assuming it goes through because other research groups will have access to these trees to help us really determine if they're going to be able to be the tool for restoring the American chestnut. One other thing that I think it's important to remember is just because this tree is deregulated doesn't mean it's immediately going to be planted in the forest. We need to diversify this tree with a variety of backgrounds of wild American chestnuts so that we actually have a population that can go back into the forest and that's going to take a few generations of crossing. There are some tools we can use to make that work go a little faster, but it's not going to happen overnight. But we're going to have plenty of time to assess the program as it moves forward for its effectiveness.

Laura Knoy: Well, permitting processes can move slowly, regulate regulatory processes can move slowly. Trees certainly grow slowly. So, Tom, I guess I'll throw this to you. How has the fact that we've been in a pandemic since early March, people are not, you know, meeting in person? I guess people are going out in the field, but you can't go out in large groups. So how has the pandemic affected the work that you're doing, Tom, on the American chestnut and its restoration?

Tom Klak: Right now, the pandemic, of course, has affected everything, and I'm sure all our listeners, your listeners are thinking about that every day, every sort of common everyday activity is shaped by the pandemic. And all my students went home to their their home states when the pandemic struck back in March. We've been able to reconstitute though, I've been doing a lot of work alone in my lab and also in the field. As you mentioned, we can do work outside. And I've hired a student to work with me as an undergraduate, and is a graduate, and now lives in Maine. And he's been tremendously helpful. His name is Flynn Willsey. So we've made a lot of progress and what we've been doing is developing the pollen from the transgenic chestnut in the University of New England greenhouse and a plant chamber, a high intensity light chamber. And this relates to Kendra's point about the need to diversify the genetics because the transgenic begins as a clone and we need to bring a variety of different genetic mixtures together. That's why going back to an earlier point, it's worth underscoring that listeners can help by finding wild trees and growing them in their yards like some of the callers mentioned they're doing. So we need genetic diversity from the wild population, coupled with the wheat gene blight tolerance aspect in order to bring the tree back, because the wild tree has everything going for it except for the fact that the imported blight kills it. And so that's the one thing we're inserting. Otherwise, the transgenic tree is ninety nine point nine nine nine percent pure American.

Laura Knoy: So here's a question for you, Tom. You mentioned earlier about how traditional crossbreeding had not had the positive results that you had hoped for, given the complexity of all the genes from that Chinese chestnut that for a long time researchers had tried to cross-breed into the hardier, blight resistant American chestnut. And so that has been going on for a long time, has not given the results that were hoped for. There are concerns, though, about these genetically engineered trees. What about, Tom, the biocontrols that we talked about earlier, finding a way to stop the blight?

Tom Klak: Right. Kendra mentioned before that that's sort of the third leg of our approach, and it's more limited than the other two being the biotech approach and the the breeding approach because it only affects individual trees. So we can have some success with biocontrol and to keep a particular tree alive for a little bit longer, which is a good idea. But it cannot solve the problem of trying to bring back a tree that had perhaps four billion individuals throughout its eastern range. So I've used it myself to keep some trees alive that we've pollinated this summer. But it's not an overarching solution like the other two big, major thrusts of the American Chestnut Foundation.

Laura Knoy: We also touched on this earlier. And Doug, I'll throw this to you. You know, New England has other beloved trees that are threatened. The elm, the ash, the hemlock. We've done stories on those. How do you feel, Doug, about the argument that let's focus our research efforts, our research time, our research money on those trees that are still with us instead of trying to revive a tree that is mostly gone? What do you think, Doug?

Doug McLane: Well, you asked the one of us... that is a complicated answer because I'm almost as involved in American Elm restoration. It's a wonderful tree. That we all remember when we were younger. And the elm does have blight resistant varieties, so it's not nearly as crucial. The chestnut does not have, as much as we all hope whenever we find a big tree, ooh, maybe this one has resistance. They don't seem to, they all seem to get the blight. Many American elms reach large size and reproductive stage. So you're right. We have the the beach tree and the elm tree and the chestnut tree are all dealing with blights imported from Asia. And yeah, we have to think big. I do know that ESF is working on the American Elm with transgenics and who knows where this will lead. So the goal right now is to find one tree, which is the chestnut, and show that it will work and then we can diversify. Quickly, I want to remind the caller that called in and a lot of people that have a chestnut or two or three that they look after, what can I do for it? And Kendra had mentioned that probably a dose of fertilizer is not generally what they need. But one thing that is very, very helpful and easy to do, which is to put a big mat of woodchips. You can get them free from your local tree people that have...they're looking for places to dump them. Probably not bark chips that you get at a nursery, but actual hardwood, soft wood chips. If you put a big layer of them under a chestnut tree, it can help mimic the forest floor, which is what these trees want.

Laura Knoy: All right. Well, we have to wrap it up there. We could have talked a lot longer, but I do want to direct people to the website. There are more resources there and some pictures as well. And I really want to thank our guests for being with us. Kendra Collins, New England regional science coordinator for the American Chestnut Foundation. Thomas Klak, University of New England, professor of Environmental Studies and vice president of the Foundation's Maine chapter. And Doug McLane, president of the Vermont New Hampshire chapter. This is The Exchange on NHPR.

Read the original post:

What Will It Take to Restore the American Chestnut Tree? - New Hampshire Public Radio

Demand Scenario of Site Directed Mutagenesis Systems Market to Remain Positive Through 2029 – Lake Shore Gazette

Site Directed Mutagenesis is an in vitro artificial technique for creating mutation or alteration by insertions, deletions into any targeted DNA sequence. Mutations in the DNA can cause serious health issues like cancer. To understand the specific gene has become important in order to overcome major health issues. The site directed mutagenesis systems is technology PCR-based diagnostic technique. The genetic engineering using site directed mutagenesis can be used to produce insulin, modified vaccines and other drugs. Protein engineering using site directed mutagenesis has also proven useful in the production of interleukin, anticoagulants which has major contribution in the healthcare. Site directed mutagenesis systems provides simple, convenient and highly efficient, methods to create mutations in the targeted plasmid. The Gene Art Site-Directed Mutagenesis PLUS System brings our mutagenesis to the next level by making single or multiple alterations in the targeted gene. The Site directed mutagenesis systems are being widely used due to their availability and maximum adoption.

To remain ahead of your competitors, request for a sample here@ https://www.persistencemarketresearch.com/samples/31390

Protein engineering has growing demand having the therapeutic as well as diagnostic values. Genetic engineering has major uses in medicine, research, industry and agriculture. Genetic engineering has been used in medicine to produce insulin, human growth hormones, human albumin, monoclonal antibodies, antihemophilic factors, vaccines, and many other drugs in turn driving the growth of site directed mutagenesis systems market. Infertility has become major problem in the young generation in the recent years. Genetic engineering has developed follistim, a genetically modified hormone used to treat infertility. Gardasil 9, a recombinant drug for treating Human Papilloma Virus causing cervical cancer in women, all these recombinant products are developed using genetic engineering leading to the growth of site directed mutagenesis systems market. These results by manipulations in the gene using site directed mutagenesis technology are unknown whether the gene shows desired response also, these manipulations are not reversed posing several ethical issues. Cloning practice has been banned due to its undesired results, leads to decline the growth of site directed mutagenesis systems market. Antibiotic resistance is a major disadvantage of genetically modified food products, leads to restrict site directed mutagenesis systems market.

The global site directed mutagenesis systems market is segmented on the basis of site, device type, application, end user, and region.

Based on site, site directed mutagenesis systems is segmented into following;

Based on device type, site directed mutagenesis systems is segmented into following;

Based on application, site directed mutagenesis systems is segmented into following;

Based on end user, site directed mutagenesis systems is segmented into following

To receive Methodology request here@ https://www.persistencemarketresearch.com/methodology/31390

The market of multiple site directed mutagenesis systems market has gained more importance due to increases number of alteration sites. Multiple site directed mutagenesis devices market is highly valued to as it can be used to code different alterations. Rising prevalence chronic diseases is the prime factor responsible to increase the growth of site directed mutagenesis systems market over forecast period. Based on device type, the real time PCR based site directed mutagenesis devices market expected to be highest revenue generating segment owing to its ability to provide results in less time. The genetic engineering has proven its importance by developing modified hormones like insulin increasing its high demand for treating diabetes. Based on end user the site directed mutagenesis systems market will be dominated by diagnostic laboratories over forecast period.

Globally the site directed mutagenesis systems market especially includes in North America, Europe and Asia-Pacific, Latin America, and Middle East & Africa. North America holds the maximum share in site directed mutagenesis systems market globally. Site directed mutagenesis device market will experience rapid growth during the forecast period in APAC. Due to emergence of new small players ultimately increasing the growth of site directed mutagenesis systems market in Latin America and MEA.

To receive extensive list of important regions, Request TOC here @ https://www.persistencemarketresearch.com/toc/31390

The major player of site directed mutagenesis systems market include

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.

See more here:

Demand Scenario of Site Directed Mutagenesis Systems Market to Remain Positive Through 2029 - Lake Shore Gazette

Littered with Progress – Pleasanton Express

The other day on the internet, I saw an old commercial of a semi truck that had these words painted on the side: JONNY KAT, KITTY LITTER. For some reason that had a profound affect on me. Imagine a semi full of kitty litter! Forty thousand pounds of scented, colored and packaged cat box contents!

That has to say something about our affluent society, about the shape of our civilization. Some of our past inventions are quite practical and ingenious. The self-sealing, puncture proof tire, mercury lights, insecticide ear tags, microwave ovens, the Salk vaccine, four-wheel drive, frozen orange juice and boxed beef. Pistachio tree roots are susceptible to certain kinds of root rot. But peach tree roots are more resistant. So the pistachio growers graft pistachio trunks onto peach tree roots. Clever.

Consider how much artificial insemination has done to improve the quality of our livestock production. Genetic engineering is space-age technology.

But sometimes when we strive to achieve we go off the deep end. Take the cell phone. When they first appeared on the scene they were expensive, heavy and required two hands to operate. Now you can get a disposable one with a camera that adds, subtracts, calculates square roots, tells you the time in Singapore, wakes you up, plays you a tune, gives you the weather and news, takes your pulse, calendars all your events and reminds you of them all, and controls all appliances in your house! What Id like to find is a cell phone that gives me more hours in a day!

And speaking of rotting edges affluence, how about aerosol cheese spread? I thought plasticwrapped, individual cheese slices were pretty decadent, but you can also foam it onto your crackers like shaving cream.

Yep, weve surrounded ourselves with creations that have gone a step beyond their original purpose; fender skirts, square headlights and veterinarians with PhDs. Some might even include Pekingese, Chihuahua or Appaloosa in that group, but I know how sensitive animal breeders are so I certainly wouldnt include them. Obviously our adventures into the extreme or entertaining are useful. We learn and perfect by doing.

Well, my digital ballpoint pen is playing Mammas Dont Let Your Babies Grow Up To Be Cowboys, so I guess its time to brush my teeth and hit the sack. I hope the batteries are still charged in my computerized flosser. http://www.baxterblack.com

Read more:

Littered with Progress - Pleasanton Express

North America Genome Editing Market is expected to reach US$ 4148.1 Million by 2027 with CAGR of 17.2% – Market Research Correspondent

Genome editing is a method of making specific changes to the DNA of a cell or organism. Enzymes cut DNA at specific sequences that, when repaired by the cell, change or edit into the sequence

Genome editing, or genome manipulation, or gene editing is a type of genetic manipulation in which DNA is inserted, deleted, modified, or replaced in the genome of an organism. Unlike early genetic engineering techniques, which randomly insert genetic material into the host genome, genome editing directs the insert to a specific location.

The North America genome editing market accounted to US$ 1,234.5 Million in 2019 and is expected to grow at a CAGR of 17.2% during the forecast period 2020 2027, to account to US$ 4,148.1 Million by 2027.

Biotechnology is a broad field of biology that utilizes biological systems and organisms to develop or manufacture products. Depending on the tool or application, it often overlaps with the relevant scientific discipline. Biotechnology is the technology of developing or creating various products using biological systems, living things, or parts thereof. Baking brewed bread is an example of a process that is part of the concept of biotechnology (using yeast to produce a desired product).

The North America Genome Editingmarketis growing along with the Biotechnology industry, but the market is likely to slow down its growth due to the shortage of skilled professionals, suggests the Business Market Insights report.

The Business Market Insights subscription helps clients understand theongoingmarket trends,identifyopportunities, and make informed decisions through the reports in the Subscription Platform. The Industry reports available in the subscriptionprovidean in-depth analysis on various market topics and enable clients to line up remunerative opportunities. The reportsprovidethe market size & forecast, drivers, challenges, trends, and more.

Ask for FREE Sample Copy of this report at https://www.businessmarketinsights.com/sample/TIPRE00003907

According to International Services for the Acquisition of Agricultural Biotechnology Applications (ISAAA), 2017 statistics show that 53 developing countries plant 53%, which is about 100.6 million hectares of global biotechnology hectares. 47% of the five developed countries, which has a share of about 89.2 million hectares. The growth trend of GM crops is expected to grow in the future. In addition, the data revealed that, out of the 24 countries that cultivated biotech crops in 2016, 18 were considered biotech mega countries. About 50,000 hectares of genetically modified crops are grown in these countries. The United States remained the top producer of genetically engineered crops worldwide. The country planted 75 million hectares in 2017, which covered 40% of the worlds biotech crop planting. Similarly, Brazil is second with 50.2 million hectares, accounting for 26% of world production.

These factors are expected to offer broad growth opportunities in the Biotechnology industry and this is expected to cause the demand for GENOME EDITING assays in the market.

Business Market Insights reports focus upon clientobjectives, use standard research methodologies and exclusive analytical models, combined with robust business acumen, which providesprecise and insightful results.

Business Market Insights reports are usefulnot only forcorporate and academic professionalsbut also forconsulting, research firms,PEVCfirms, and professional services firms.

NORTH AMERICA GENOME EDITING MARKET SEGMENTATION

By Technology

By Application

By End User

By Geography

Company Profiles

Full Report subscription with pay as per requirement at https://www.businessmarketinsights.com/TIPRE00003907/checkout/basic/single/monthly

(30-day subscription plans proveto beverycost-effectivewith no compromise on the quality of reports)

Benefits with Business Market Insights

About Business Market Insights

Based in New York, Business Market Insights is a one-stop destination for in-depth market research reports from various industries including Technology, Media & Telecommunications, Semiconductor & Electronics, Aerospace & Defense, Automotive & Transportation, Biotechnology, Healthcare IT, Manufacturing & Construction, Medical Device, and Chemicals & Materials. The clients include corporate and academic professionals, consulting, research firms,PEVCfirms, and professional services firms.

For Subscription contact

Business Market Insights

Phone :+442081254005E-Mail :[emailprotected]

See the original post here:

North America Genome Editing Market is expected to reach US$ 4148.1 Million by 2027 with CAGR of 17.2% - Market Research Correspondent

Companies That Want To Make Pharmaceutical APIs Will Be Producing Commodities. Heres What They Should Consider – Forbes

U.S. President Donald Trump announced that Eastman Kodak will receive a loan to manufacture ... [+] ingredients used in pharmaceuticals. (Photo by Alex Wong/Getty Images)

The news that Eastman Kodak Company had received a U.S. government loan to begin the production of active pharmaceutical ingredients (APIs) domestically is recognition of the risks associated with the far-flung supply chain for these critical materials. The Europeans have recognized these risks as well. But that doesnt make the economic challenge of doing this successfully any easier. The problem is that most APIs are commodities.

I spent seven and a half years at Kodak beginning in 1997 running their consumer digital operation, and during that time I got to know the manufacturing people in film and chemicals. The synthetic chemicals team, or Syn Chem as it was known, was an extremely capable crew. They knew what it meant to take a chemical synthesis from the laboratory to an industrial scale, and they practiced their trade on extremely complex materials photochemicals, dyes, couplers complicated molecules that are difficult to make. They knew what solvents (the liquids that you ran the reactions in) you used were important, because when youre done you had to get rid of all the waste products. You couldnt just dump the waste in the local river. You also liked to optimize reaction times (known as reaction kinetics), the amount of energy consumed, the use of dangerous intermediates, all things that were of lesser concern when you were operating at lab scale than when you were doing them at industrial scale. So there is little doubt in my mind that the Kodak team (I hope they havent lost too many of the Syn Chem crew) could make just about anything.

A chemical mixing machine in an Eastman Kodak Corp. manufacturing facility in Rochester, New York. ... [+] Photographer: Daniel Acker/Bloomberg News

But as I said, the first problem with APIs is that most of them are commodities, which means that batches of them are readily substitutable for one another regardless of where they came from. Chemicals are easy to characterize. Modern analytical techniques such as gas chromatography (GC), liquid chromatography (LC), and mass spectrometry (MS), often combined as GC/MS or LC/MS instruments, can be used to analyze a drum or a tank car load of chemical, and tell you exactly what is inside, along with what kinds of impurities and how much of each are mixed in. So if you have the choice among multiple batches that all have a high enough purity level and none of the contaminants that you cant deal with, the only difference is the price.

The second problem with domestic production of APIs is that they are largely tradable. A good is tradable to the extent that it doesnt need to be manufactured close to where it is consumed. Most products are tradable because the cost of shipping them is a relatively small percentage of their value, so if it costs less to make something in China and the shipping cost is less than the difference, it makes economic sense to make it there and ship it. Thats why the U.S. imports so much of everything from China the production costs differentials historically have been much higher than the shipping costs.

The third problem is drug pricing, especially for generics. No consumer likes higher prices, and the President himself have been putting pressure on manufacturers to lower drug prices. But if drugs are made from tradable commodities, that means the companies who formulate the drugs are driven to use the lowest cost sourcing, and that is generally not domestic (usually this means China or India). Once again we face the dilemma we want to make it in the U.S., but we dont want to pay for the higher costs.

Invest in process innovations. Employing newer manufacturing processes historically has been one of the most effective ways to disrupt incumbent manufacturers by offering lower costs. After World War II, European and Japanese steel manufacturers who had to rebuild their industries from scratch were the first to employ new manufacturing processes like basic oxygen and continuous casting. The new processes were more efficient, and their low-cost exports of steel to the U.S. started the long decline of the American steel industry. Korean and Taiwanese flat-panel display manufacturers were able to employ newer, more efficient equipment than the Japanese producers who started the industry, and now the same Korean and Taiwanese companies are under pressure from Chinese companies who are using even newer equipment.

A coming revolution is continuous flow chemical manufacturing, in which compact, continuous flow reactors promise far more efficient reaction processes. I had the opportunity to visit Snapdragon Chemistry two weeks ago, and it is amazing what they are doing. I had to rush back to the Baker Library at HBS and read up on chemical synthesis route design, which is the term used to describe a strategic development process for APIs. I have about 20 more scientific papers to read on this topic to get a better understanding, then you can ask me more. The Defense Advanced Research Projects Agency (DARPA) has been beating this drum for some time now. Once again DARPA is one of the more visionary agencies we have.

Invest in biomanufacturing. Biomanufacturing uses living systems to produce chemicals and biomaterials. Living things already produce the most complex chemicals imaginable, so the idea is to harness cells by using genetic engineering to make new things. This is already used for many biopharmaceuticals, vaccines, and industrial enzymes, but researchers in the field think much more can be done. DARPAs Living Foundries: 1000 Molecules program is funding a lot of research in this area, so the possibilities are intriguing.

One country we might look to for an example is Denmark, where there is a strong cluster of firms who use fermentation to produce a wide range of products. Novozymes, based inBagsvrd outside of Copenhagen, is the world leader in industrial enzymes. Industrial enzymes have been the source of many advances in household laundry detergents like Tide, and are widely used in industries like textiles. Denmarks cluster of fermentation expertise traces back to the Carlsberg brewing company. The Carlsberg Laboratory, established in 1875, was chartered to develop a scientific basis for malting, brewing, and fermenting operations, and ongoing research there and knowledge spillovers have made the region a world leading cluster.

Where in America might we find people who know how to do this? According to the Brewers Association, the COVID-19 pandemic has been hard on many breweries, and it reports that A majority of breweries do not think their business can last three months given current conditions, suggesting thousands of closings. Brewers were the foundation of a lot of pharmaceutical manufacturing in India. As longs as the U.S. government is spending money at such a prodigious rate, maybe we could fund an agency to help brewers move into manufacturing chemicals.

Leverage FDA certification processes. One other thing the U.S. could consider is the FDA certification process for pharmaceutical manufacturing. How far back in the supply chain should it require certification? It probably doesnt need to start all the way back at earth, wind, fire, and water, but by strategically picking where it requires inspection, it could shape behavior along the supply chain. We would call that a non-tariff barrier.

The global pandemic is reshaping supply chains in many industries. The economics on some of the new designs havent been tested yet, but with some strategic thinking and actions, we could end up in a better place.

See the rest here:

Companies That Want To Make Pharmaceutical APIs Will Be Producing Commodities. Heres What They Should Consider - Forbes